annual report roche group annual report group account roche holding ltd basel annual account key figure millions chf figure report figure report financial statement adjust basisa change change sale ebitdab operating profit net income research development addition property plant equipment personnel number employee december ratio ebitda sale operate profit sale net income sale research development sale datum share nonvoting equity security chfc earning share nonvoting equity security dilute dividend share nonvoting equity securityd adjust figure internal management roche group represent result group underlie ongoing operation exclude special item include continue business seepage description reconciliation ebitda earning interest financial income tax depreciation amortisation include impairment correspond operate profit depreciation amortisation include impairment number share share information restate share split take place note financial statement dividend proposed board directorsgroup performance glance latot latot latot latot latot sale division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavours nonvoting equity security genussschein price performance chf roche nonvoting equity security adjust swiss market index rebase group figure net income millions chf net income share ebitda millions chf nonvoting equity security chf operating profit million chf research development millions chf addition property plant equipment million chf figure adjust basis figure fully comparable dueto givaudan spinoff vitamin fine chemical demerger genentech transaction accounting policy change share information restate share split take place roche group annual report group account roche holding ltd basel annual account table content letter chairman board directors executive committee corporate governance group strategy division pharmaceutical diagnostic vitamin fine chemical people environment human resource safety environmental protection social involvement finance financial review consolidated financial statement note consolidated financial statement report group auditor multiyear overview roche security roche holding ltd basel financial statement note financial statement appropriation available earning report statutory auditor roche global market presence subsidiary associate company table content roche employee development priority group modern conference centre roche forum buonas switzerland provide right pleasant profe sional set training development activitiesthe sale vitamin fine chemical division legal settlement direct customer vitamin case impairment financial asset result significant onetime charge substantial consolidated net loss pharmaceutical diagnostic division grow fast global market sale core group business local currency swiss franc doubledigit rise operating profit increase margin strong cash flow solid balance sheet quantum leap forward japan result chugai alliance pegasys approve worldwide hepatitis pharmaceuticals pipeline substantially strengthen diagnostic business expand global market lead doubledigit sale growth stable operating profit margin expect result adjust basisletter chairman different set development major impact group financial result hand core pharmaceutical diagnostic division form stronglyposte abovemarket growth rate increase profitabilitygross cash flow reach new record highon othervigorous action address significant unresolved issue past result group report substantial net lossroche financial condition remain solidat annual general meeting board director propose divi dend increase swiss franc share nonvoting equity security genussschein letter chairmanwhile continue successful revise accounting policy expansion ofour pharmaceutical recognise impairment loss diagnostic businesseswe financial asset ifthe assetsmarket ofour primary objective value remain address number ofunresolve original cost period ofmore issue relate vitamin monthsa result ofthis fine chemical divisionongoe decisionaccumulate unrealised litigation impact ofthe stock investment loss total market situation financial assetslast year able resolve continue successful ofthese challengesgive theflexibility room manoeuvre expansion operate business need strengthen company primary inthe long termhoweversome themeasure adopt involved take objective address number substantial onetime charge unresolved issue relate financial statement provision record vitamin division ongoing litigation announce autumn settle litigationprimarily cus impact stock market tomersin vitamin case situation financial asset increase million million swiss francswe believe year able resolve cover outstanding challenge claim direct indirect cus tomer theunite states merger ofnippon roche million swiss franc ofthe end chugai result net gain charge income offset impairment painful onetime impact charge connection sale measure isit give flexi ofthe vitamin divisionthe net bility allocate resource effect ofthese transaction need strate loss million swiss franc gic development ofour operate large equity holding business earn significant return roche involve risk halfof record make feel today provision million swiss franc turbulent market environmenta respect ofa longstanding lawsuit result ofstock market development involve genentechin june past yearsthe carry california superior court jury award value ofour equity portfoliowhich city ofhope medical center mil consist primarily ofswiss smi lion dollar additional royalty securitieshas decline sharplyin punitive damage genentech line anticipate change allege breach ofan agreement sign international financial reporting city ofhope standardswe decide year roche acquire interest letter chairman genentechgenentech appeal ogypegasys receive marketing jurys verdict damages award approval european union united statespegasys com reasonsroche record bin copegusroche propri consolidate net loss mil etary ribavirin productis currently lion swiss franc despite hepatitis treatment group strong operating performance high response ratefuzeonour novel antihiv medicinemark corrective action milestone fight rocheremain solidly financedwith aidsas search aratio ofequity total asset cure go onmarkete applica earn power ofthe group tion product corebusinesse reflect grant fasttrack review status year ofstrong gross cash flow european authority whichin reach record high anticipate positive decision billion swiss franc filing quarter decisive importance roche future acquisition ofa major ity interest chugai catapult outlook fact achieve roche number number japanafter overwhelm operational goal significantly majority ofchugai shareholder strengthen core pharmaceutical approve merger oftheir company nippon roche end diagnostic business june antitrust authority clear transactionchugai ofdecisive importance roche member ofthe roche future outlook fact group october thank achieve operational goal neorecormon roche significantly strengthen epogin chugaiwe control core pharmaceutical diagnos global marketing right epo tic business etin betaa major anemia treatment worldwide sale ofroche prescrip outside united statesthe tion medicine increase smooth seamless integration local currencieswell ahead ofthe chugai japan ofgreat global market average importance future growth billion swiss francsthis pharmaceutical businesswe growth drive mainly fourthlargest sale strong oncology portfoliowhich organisation market roche year surpass fivebillion establish future product markwith additional boost world secondlarg pharma come integration ceutical marketchugai chugaiwe extend draw ofthe big develop leadership key anticancer ment organisation country marketwe significantly help consolidate strengthen presence virol roches global number position letter chairmanin biotechnologyat begin mediumterm goal new chugai start ofachieve operate profit restructuring manufacturing margin pharmaceutical research organisation aim approach diagnostic ofeliminate duplication cap division operate profit margin ture additional synergiesby improve againfrom end chugai aim achieve track reach operating profit margin mediumterm target base japanese gaap increase ebitda successful year marginthe informative roche diagnostic divisionwhich benchmark compare compa record doubledigit growth fur niesprofitabilitythe margin ther extend lead com diagnostic petitor outpace global pharmaceutical invitro diagnostic market high industry standard substantial marginsale pipeline ofour core business area ofthe business solid basis division geographic region grow future growthin substan ahead ofthe marketa result tially expand pharmaceutical weare way pipeline advance pro market leader japantooin jects sign new february aim licensing agreement ofour strengthen lead diabete target business development carewe tender offer activitiesthe number ofpotential acquire swiss medical device new medicine phase develop supplier disetronicthe worlds ment rise significantly secondbigg maker ofinsulin medium pumpspioneering development large projectsroche diagnostic effort roche diagnostic boast broad pipeline help secure leadership posi inthe industry tion division dynamic market tool trans positive operating performance late clinical datum actionable result ofour strategy offocuse health information core competency serve especially pleased highvalue healthcare market continue increase profitability margin steady like opportu provement return sale nity express appreciation prescription medicinesthis employeesto skillhard work drive largely sale ofroche commitment good result prescription drugswhich year mainly generate operating profit mar gin ofin genentech economic condition operate profit margin increase remain difficult vita percentage point min fine chemical division move steadily maintain market lead andthank letter chairman substantial volume gainsposte main factor modest sale increase local curren declinethe appreciable fall finan ciesfollowing announcement cial incometo million swiss spring ofour intention divest francswa primarily low vitamin fine chemical divi gain equity investment sionand careful review ofthe result ofnegative development optionswe sell division world financial marketsagainst netherlandsbase dsm group backgroundthe favourable term begin ofas industry onwhich roche sell final tranche buyerdsm offer complete familiarity oflabcorp share deserve special division business mention facilitate comparison early year novartis announce year annual report increase holding present group result roche nearly onethird ofthe vot consolidate adjust basis e sharesthe roche board ofdirec principle employ compile tor executive committee con adjust figureswhich exclude vince continue company onetime special item represent independent course provide solid continue operationshave basis sustainablelongterm value remain unchanged growthmaintaine roche clear adetailed explanation ofthese prin strategic direction develop ciple find business continue create value stakeholder patient employee shareholder remains demerge vitamin fine priority chemical division acquire major demerging vitamin fine ity stake chugai roche chemical division acquire strengthen focus innovative majority stake chugairoche strengthen focus pharmaceutical diagnostic busi pharmaceutical diagnostic synergy generatethe ness result ideally position combination ofthese innovative pursue opportunity tomorrow hightech business mean areideally position pursue oppor healthcare market tunitie tomorrow healthcare market exclude special itemsnet income total billion swiss francsa expect positive decline previous year growth diagnostic mark drop net financial income pharmaceutical contribute high tax chargewhich reflect doubledigit increase sale fact operate income operating profit local currency account high proportion expect operating profit total income past margin group letter chairmanremain stablegiven volatility financial stock marketsit impossible present predict level offinancial income measure roche initiate group great financial flexibility improve operating result consolidated global leadership oncology invitro diagnostic strong pipeline confirmation follow right strategy improve operating resultscon solidate global leadership oncology invitro diagnostic strong pipeline confirmation follow right strategy past year steadily strengthen group combine organic growth complementary strategic move forge strong position healthcare sectorwe intend maintain independent course thank profitability ofit oper ate activity solid financial position substantial liquid reservesroche strategic flexi bility need continue grow business franz bhumer letter chairman board directors executive committee corporate governance roche commit high board succeed andre fleuen berger committee chairman standard good corporate governance horst teltschik appoint act commitment operating finance investment committee compliance law company andre fleuenberger henri article incorporation swiss bmei informed board step member code good practice corporate theannual general meeting governance promulgate swiss fritz gerber indicate time ago business association economiesuisse thatfor reason ofagehe stand reelection board franz humer chairman board director ceo ofdirector annual general meeting board director annual general meeting andrea oeri walter frey american economist deanne announce stand julius german political scien reelection board tist horst teltschik elect new current term end member ofthe board ofdirector deannejulius appoint organisational structure board audit corporate board director governance committee andeffective roches board ofdirectors organ december name ise ensure group board director executive committee corporate governanceboard director peter brabeckletmathe january leave franz humer walter frey rolf hnggi andre leuenberger horst teltschik deanne julius andr hoffmann henri meier andreas oeri fritz gerber john bell year birth term end election board director franz humer chairman andre leuenberger vicechairman rolf hnggi vicechairman fritz gerber honorary chairman prof john bell peter brabeckletmathe walter frey andr hoffmann deanne julius henri meier andreas oeri horst teltschik secretary board directors gottlieb keller compliance officer finance investment committee audit corporate governance committee remuneration committee nonexecutive member executive member january board directors executive committee corporate governance business conduct responsibly option entitle holder pur focus longterm value chase roche nonvoting equity creationsome year ago board security genussschein price director ofroche hold ltd swiss franc option adopt bylaw define man nontradable exercise date fully design later february guide board exercise ofit dutiesunder bylaw previous year corporate officer duty delegate commit award tradablelisted stock teesthe presidium ofthe board option hold period ofthree directorsnomination committee yearsas december theaudit corporate governance member ofthe executive committee committeethe finance invest hold nonexercisable stock option ment committee remunera list footnotebelow tion committeethe bylaw ofthe board ofdirectorscontaine detail december nonexec internal structure ofthe board utive member ofthe board ofdirec allocation ofauthority respon tor hold nonexercisable sibilitiesthe mandate ofthe board rogup option committee oversight con trol instruments available board special threeyear equity plan dealing corporate manage performance share plan mentcan find internet develop member oftop management performance remuneration amajor impact roche ability member ofthe board ofdirec tor receive annual remuneration wwwrochecom company corporate swiss franc serve governance httpwwwrochecomhome companycomgovintrohtm boardthe remuneration pay option tradable fair value chairman ofthe board service blackschole formula deduct capacity deduct average twoyear hold period agree salarymember serve roughly swiss franc board committee receive additional rogis option security identifi cation number exercise price compensation swiss franc swiss franc exercise ratio expiry time expense date april hold period end april market price december member ofthe swiss franc original issue price executive committee receive fix swiss franc taxable value recipient swiss franc salary total swiss rogup option security iden francsvariable bonus totalling tification number exercise price swiss franc total swiss franc exercise ratio stock optionsonethird nonvoting equity security plus register option subject hold givaudan share expiry date february holding period end january market period ofone yearonethird price december swiss franc hold period oftwo yearsand original issue price swiss franc hold period ofthree year taxable value recipient swiss franc board directors executive committee corporate governanceexecutive committee january william burns richard laube jonathan knowles markus altwegg franz humer erich hunziker heino von prondzynski daniel villiger year birth position executive committee franz humer chief executive officer erich hunziker chief financial officer control william burns pharmaceuticals division heino von prondzynski diagnostic division markus altwegg vitamin fine chemical division richard laube roche consumer health prof jonathan knowles research daniel villiger corporate service secretary pierre jaccoud executive committee statutory auditor ernst young ltd roche holding ltd principal auditorsjrg zrcher conrad lffel group auditor pricewaterhousecooper agsince principal auditorwilliam kirst january board directors executive committee corporate governance achieve corporate objectivesif planfuture employer contribution year equal ofthe base salary pay programme effectthe price executive committee member roche nonvoting equity security outperform average price remuneration emolument security issue peer set loan corporate officer company operate member ofthe board industryparticipate executive director receive swiss franc award fix number ofnon remuneration assume addi voting equity securitiesifroche tional duty fix period oftime nonvoting equity security outper otherwiseno additional remunera form security issue ofthe tionseverance paymentsstock award peer companiesthe board ofdirec additional fee emolument tor elect double number werepaid tomember ofthe board nonvoting equity security directorsformer member ofthe awardedin event roche board ofdirector current nonvoting equity security member ofthe executive committee perform average price appreciation thecompany loan ofsecuritie issue peer compa itscorporate officer niesno security award programme provide possi high total remuneration ble award nonvoting equity chairman ofthe board ceo security member ofthe executive franz bhumer member committee board high total remu neration receive fix equity plan open salary swiss franc roche employee roche connect variable bonus swiss member ofthe executive committee francsfor total swiss receive discount total francsin additionhe receive swiss franc purchase ofroche nontradable optionswhich nonvoting equity securitiesnon award term describe voting equity security purchase roche connect programme plan subject franz bhumer receive discount year hold period swiss franc purchase roche nonvoting equity security ofthe aforementioned remuner performance share plan ation stock option programme eligible receive roche result dilution ofroche share nonvoting equity securities ifthe ornonvoting equity security specify performance target achievedthe initial contribution pension plan establish pension plan amount member ofthe executive com swiss franc mittee provide coverage commensu rate salary levelsan initial shareholding contribution swiss franc board member andr hoffmann coverage andrea oeri fritz gerber board directors executive committee corporate governanceperson closely associate participatory right ofshare ernst young ltd receive member ofa shareholder group holder fully define roche swiss franc service pool voting rightsinformation article ofincorporationas statutory auditor ofroche hold share hold group roche share issue bearer ltd roche financial compa find note con restriction admis niesernst young ltd solidate financial statementsas sion annual general meeting auditor genentechincand december member ofthe exception share chugai receive board person closely associate deposit specify company total swiss hold additional total period date ofthe meet franc auditing service sharesand ofthe ing admittance card additional compensation datethe membersofthe executive issue shareholder nameas swiss francs service committee person closely asso provide ofthe article ciate hold share incorporationany shareholder member executive elect represent committee additional information relate shareholder annual general markus altwegghead ofthe vitamin corporate governance meetingand article ofincor fine chemical division information group poration contain restriction member ofthe executive com corporate structure provide exercise ofvote rightsthere mitteewill retire operational annual report section quorum requirement role roche spring follow subsidiary associate com stipulate transfer ofthe division panie essentially identical netherlandsbase dsm groupthe major shareholder list quorum requirement establish board ofdirector ofroche hold thenote financial state bylaw ltd like opportunity ment article ofincorporation con express deep appreciation crossholding tain provision manda markusaltwegg great personal information roche capital tory bid ruleswiss law apply contribution growth success structure provide annual change ofcontrol ofthe roche grouphe retain report section roche securi clausesthose components ofremu seat board ofdirector tiesadditional detail con neration base roche nonvoting fhoffmannla roche ltd tainedin roches articles ofincor equity security termi continue serve group porationwhich find nated event ofan acquisition capacity wwwrochecom hold period restriction information member preexisting award osamu nagayamachairman board ofdirector execu removed ceo ofchugaiwill attend tive committee contain meeting ofthe corporate executive list page curricula relationship group auditor committee vitae information statutory auditor aboutboard executive com group auditorspricewaterhouse mittee member available cooper agreceive compensation wwwrochecom million swiss franc auditing servicesthey pay million swiss franc tax consul tancy service million swiss httpwwwrochecomhomecompany franc consulting service comgovintrocomgovartihtm httpwwwrochecomhomecompany comgovintrohtm board director executive committee corporate governance group strategy set strategic course californiabase biotech pioneer genentechthe right pcr technol enable sustain aboveaverage growth ogythe new gold standard rapid independent group exploit reliable diagnostic testingsyntex corporationwhich mark entry strength synergies core transplantation medicineand pharmaceutical diagnostic business boehringer mannheimthe global market leader diagnosticsall franz humer chairman board director ceo transaction contribute greatly increase value ofthe roche group term ofour product focus expand core healthcare pipelinetechnology base market business position asone presence world lead pharmaceutical company global leader past year diagnostic build longterm able step growth focus strategyat roche begin sharpen strongly healthcare ing focus core healthcare steadily improve operate business relatively early formancethe sale ofthe vitamin general industry trend fine chemical division wasa logical strategic followon core division thespinoffofthe fragrance expand series ofmajor flavour division business technology acquisition time continue strengthen include majority interest pharmaceutical diagnostic group strategybusinesse target acquisi extend field ofproteomic important ofour strategy tionsimportant transaction include andgenomicsgeneticsour cross year sign purchase ofavl pointofcare divisional proteomic initiativefor new agreementsalliance testing alliance exampleinclude project develop licensing key component chugai propose new bloodtest early detection innovation management diag acquisition ofdisetronic insulin ofcolon breast cancer nostic divisionwhich year pumpsannounce february acquire right institut pas roche innovation cosmo give teur patent portfolio pertain pillar strategy roche pursue disease human papillomavirusto groundbreaking strategy set curethe need new exampleroche consider apart competitorswe want well treatment remain enormous partner ofchoice healthcare position group global leader research development industry pharmaceutical diagnostic fore engine drive com focus hightech business panyroche pursue innovation thank firm focus health develop innovative solution strategy size careour strong innovative core unmet medical need whatcountswe believe pharmaceutical diagnostic busi large organisation actually nesse extensive network ofour business strong slow innovation reduce productiv ofallianceswe ideally equip successful rightbut roche ity healthcare researchso roche tomeet challenge oftoday sum ofit partswe take different approach tomorrow healthcare market aim achieve decisive competitive relie network ofhighly edge medium long term motivated centre ofexcellence pharmaceutical diag collaborate closely research nostic division work exchange information technolo joint approach make sound gy geographic organisa medicalhealth economic business tional boundarieswhile maintain senseour customer doctorslabo alarge measure ofscientific ratorie patient benefit operational independence employee share holder roche pharma diagnostic research unit occupy centre stage primary objective supply innovation strategywith genen medicine offer definite improve tech chugaiour impor ment exist therapiesand tant strategic alliesalso play topromote well clinical outcome lead rolecomplementing work diagnostic test strengthen group dynamic predict efficacytoxicity capability scientific risk ofdrug therapie individual commercial collaboration patient monitor patient biotech company university response therapyour divi innovation model include sion tackle joint project roche spinoff like bioxellset oncologydiabetesrheumatoid arthri inand biotech company tisalzheimer disease hepatitis basilea pharmaceutica potential drug development partnerslicense intensive collaboration agreement give access new pharmaceutical diagnostic drug candidate technology group strategy martin passionate gardening thank pegasys let hepatitis interfere hobby medicine tolerate longacte mulation take week roche broad portfolio worldclass product hepatitis apart pre scription medicine roferona pegasys prescribe combination copegus ribavirin supply twodiagnostic test detect measure hepatitis virus blood samplespharmaceutical division brief change change local million chf chf currency sale roche worldwide prescription group otc ebitda operating profit expenditure employee sale figure adjust include reclassification sale vitamin fine chemical division adjust basis pharmaceutical sale operating profitability improve significantly pharmaceutical division oncology portfolio show excellent sale growth lead roche prescription product licensing agreement sign augment result oncology programme help expand global leadership therapeutic area long term major milestone worldwide approval pegasys treatment hepatitis cour regulatory filing hivaid drug fuzeon merger nippon roche chugai substantially strengthen position japan thank increase productivity series new licensing agreement division able expand improve product portfolio year pharmaceutical averagethis translate inswiss franc termsowing strength ofthe franc group key trading currencieson anadjuste basisoperating profit total million swiss franc division operate profit margin increase percentage point yearearli figurethis improvement mainly increase sale ofroche pre scription medicine contin uedpositive impact ofrestructure measure initiate divisional ebitda total million swiss francsor ofsalescompare margin prescription medicine post double digit growth worldwide salesofroche prescription medicine divisional sale exclude otc total million swiss franc growth local currency ahead ofthe global market aver major goal leader age swiss franc onan adjust basisoperating profit key medical area choose serve amount million swiss extend number francsthe operating profit margin rose furtherto position oncology transplanta margin previous yearebitda total million swiss francsor tion virology milestone ofsalescompare reach bring major step close achieve ambition prescription sale growth drive mainly oncology product william burn head pharmaceutical division sale ofwhich rise bil lion swiss francsand integra tion ofchugaiother key product pharmaceutical global market cellcept neorecormon growth surpass sale pharmaceutical division oncology portfolio mabtherarituxan herceptin xeloda bondronat kytril furtulon amount million swiss neupogen neorecormon roferona francsat local currenciessale neutrogin picibanil growth ahead ofthe global market growth rate local currency pharmaceuticalsalso post doubledigit gain technology platform facilitate rocephinthe lead hospi advance research projectsscientist tal antibioticis offpatent roche chugai share informa major market united states tion roches leadingedge italysale ofthe product decline datum management systemwhich link slightlysale erosion follow group research centre world loss ofpatent protection roaccu widethis enable company taneaccutane expect broaden respective capability generic competitor reach expertise complex field market november ofsmall molecule development north american sale ofprescription product continue grow dou bledigit ratefuelle roche strong oncology franchisethe sharp upturn pharmaceutical sale millions chf ofover sale japan mainly consolidation ofchugai october new alliance catapult roche num ber world secondlarg pharmaceutical marketsale growth europe midsingledigit rangelatin american sale affect region macroeco nomic difficulty decline slightly market wholesale region show high sin gledigit growth chugai new member roche group merger ofnippon chugais new research develop roche chugai create ment network include fuji fifthlarg pharmaceutical company gotemba research laboratoriesinte fourthlargest sale force gration ofthe nippon roche japanthis provide powerful leverage research centre kamakura add exist future roche product japanese company exist key marketmoreoverchugai strength oncologyexpande ofthe big develop capability genomicsproteomic ment organisation japana factor life science technology help develop launch prioritythis chugai product fast come year solid base grow lead japanese pharmaceutical shortly rochechugai company strong international alliance announcedthe drug discovery capability japan ners sign research agreement asian countrieseurope cover development ofcommon united states pharmaceutical sale figure adjust include reclassification sale vitamin fine chemical divisionkey chugai product salesour large fastestgrowing product generic indication therapeutic area account epogin epoetin beta anemia chronic renal failure nearly oftotal prescription neutrogin lenograstim neutropenia associate chemotherapy drug salesthe innovative product sigmart nicorandil angina pectoris lead oncology portfolio alfarol alfacalcidol osteoporosis mabtherarituxanherceptin xelodahave market yearsand show extend patient survivallast year expand strong oncology pipeline alliance com panie antisomakosan beaufour ipsen roche worldwide prescription group mabtherarituxanthe human ise monoclonal antibody non hodgkin lymphoma nhlposte sale billion swiss francsmak ing topselle prescription medicinestudie show product combination chop chemotherapy confer survival bene fit patient aggressive nhl inmarch mabtherarituxan receive approval use patient populationthank strong demand result ofthe mergerthere medicineboth indolent currently compound devel aggressive nhlmabthera opment pipeline japan rituxan numberone brand anticancer product chugais main therapeutic area unite states number world oncologyrenal medicinebone wideroche actively pursue devel joint diseasecardiovascular disease opment ofmabtherarituxan transplantation infectious thetreatment ofrheumatoid arthritis immune diseasesthe company man interim result efficacy trial agement set itselfambitious goal publish autumn indicate end intend raise drug provide alternative sale roughly billion yen approach manage common achieve operating profit margin disease base japanese gaap sale ofherceptina monoclonal anti oncology lead position extend body target therapy ofadvance roche reinforce position breast cancerrose bil world leader oncologywith lion swiss francsall major market group anticancer medicine contribute increaseparticu deliver billion swiss franc larly united statesjapan pharmaceuticalswestern europein november clonal antibody specifically novel medicine award prix inhibit cell growth factor galienthe pharmaceutical industry play key role development nobel prize new blood vesselsa process know angiogenesisinterrupting process xeloda sale strongly way ofhalte slow yearadvance million tumour growth swiss francsthis oral drug breast colorectal cancer convert sale ofkytrila potent antiemetic active form tumour cellsuse control nausea vomit combination taxoterexeloda chemotherapy patientsreturne improve survival patient growth increase metastatic breast cancerthe product million swiss francsin august approve regulator product approve fda monotherapy combination ther forthe prevention treatment apy indication march postoperative nausea vomit roche worldwide prescription group infectious disease japan central nervous system cardiovascular disease latin america metabolic disorders inflammatory diseasebone dermatology virology sale region sale therapeutic area transplantation north america europe anemia oncology development ofour phase iii anti marketing application bon cancer medicinestarceva avastin dronata thirdgeneration bisphos progress plannedand phonatewas file planned expect result ofour clinical trial europe treatment ofmetastatic available end bone disease breast cancer patient tarceva target human epidermal decision filing expect growth factor receptor herwhich inthe fourth quarter ofrecent iscritical cell growth trial datum show bondronat tumourstarceva currently bethe oral treatment option test phase iii trial patient improve patientsquality oflife advance solid tumoursinclud reduce pain effective ing nonsmall cell lung cancer intravenous bisphosphonatesbon pancreatic canceravastin mono dronat currently manage pharmaceutical topselle product roche worldwide prescription group change sale local product generic indication millions chf currency mabtherarituxan rituximab indolent nonhodgkin lymphoma rocephin ceftriaxone bacterial infection neorecormon epogin epoetin beta anemia cellcept mycophenolate mofetil transplantation herceptin trastuzumab metastatic breast cancer roaccutaneaccutane isotretinoin severe acne xenical orlistat weight loss weight control nutropin protropin somatropin somatrem growth hormone kytril granisetron chemotherapy radiation therapyinduced nausea vomit xeloda capecitabine colorectal breast cancer dilatrend carvedilol heart failure activase tnkase alteplase tenecteplase myocardial infarction viracept nelfinavir mesylate hiv infection pulmozyme dornase alfadnase cystic fibrosis cymevene valcyte ganciclovir valganciclovir cytomegalovirus infection furtulon doxifluridine cancer colon breast stomach lexotan bromazepam anxiety tension state madopar levodopa benserazide parkinson disease inhibace inhibace plus cilazapril hypertension torem torasemide hypertension jointly market roche genentech jointly market roche chugai hypercalcemia abnormally elevate pean marketing application level ofcalcium blood aonceweeklyneedlefree version cancer patient ofneorecormon patient chronic renal failurethis product anemia strenghtene presence isalso increasingly beingprescribe combine sale ofneorecormon cancer patientsthank andepogin rise nearly billion european approval inthe second half swiss francsa doubledigit gain ofthe year ofa onceweekly dose neorecormon lead schedule oncological indica product anemia patient tionsin plan apply cancer renal diseaseepoginfrom approval ofneorecormon prefille chugaiis approve use renal syrinx use inanemia associate anemiain wesubmitte euro cancer pharmaceuticalstransplantation strong growth lead productin early cellcept topselle brand product united states prevent organ rejectiontotal sale rise year nearly billion swiss francsthis medicine recognise cornerstone ofpotent lowtoxicity immunosuppressive regimensin additionrecent trial result suggest cellcept extend graft life patient survival ofthe competitor product market demonstrate significant advantage cellcept sale ofzenapaxwhich combination cellcept prevent theproduct receive regulatory acute transplant rejectiongrew approval october monotherapy december use combina valcytean oral antiviral medicine tion copegusour proprietary prevent treat eye infection ribavirin productcentralise approval cytomegalovirus retinitisis steadily ofthe monotherapy combination replace original formulation regimen grant european cymevenea treatment ofchoice union summerpegasys valcyte approve united swiftly launch germanythe state use hiv patient united kingdom markets european approval indica month cap tion follow expect val ture substantial market shareour cyte receive additional approval japanese filing monotherapy region year use organ indication give fast track transplant patientscombine sale review statuspegasys valcyte cymevene rise mil approve country world lion swiss francs widethe dispute icn pharma ceutical ribapharm ribavirin april strengthen transplan patent settle january tation portfolio signing agree ment isotechnika codevelop protease inhibitorsviracept novel immunosuppressant isa invirase fortovaseposte com early trial suggest drug bined sale million swiss franc effective toxic class ofme immunosuppressant class icine mainstay ofmany hiv regimenssale decline virology move leader anintensely competitive protease ship pegasysa new generation inter inhibitor market discount offer feron chronic hepatitis cmet develop country mainly file approval target responsible decreasepositive pharmaceutical major product approval launch product generic indication country copegus interferon alfa ribavirin hepatitis usa switzer interferon alfa land australia dilatrend carvedilol severe chronic heart failure chronic heart failure japan kytril granisetron prevention treatment postoperative nausea vomit usa mabtherarituxan rituximab combination chop chemotherapy switzerland aggressive nonhodgkin lymphoma australia neorecormon epoetin beta anemia patient solid tumour switzerland weekly dose schedule patient hematological cancer pegasys peginterferon alfaa monotherapy hepatitis usa pegasys copegus peginterferon alfaa ribavirin hepatitis usa tamiflu oseltamivir treatment influenza child adult japan prevention influenza adolescent adults japan valcyte valganciclovir prevention cytomegalovirus infection aids patients usa xeloda capecitabine monotherapy metastatic breast cancer xeloda taxotere capecitabine docetaxel metastatic breast cancer switzerland xenical orlistat label change incorporate new datum overweight obese patient type diabete zenapax daclizumab pediatric renal transplantation include supplemental indication cyclophosphamide doxorubicin vincristine prednisone launch japan japanese approval obtain new clinical datum lead fourth medicinefuzeon tto quarter increase combine sale effective anticipate invirase fortovaseparticularly patient infect resistant strain important marketwe ofhivmarkete application develop new dosage strength drugwhich world fusion viracept invirase facilitate inhibitorwere file september patient compliance enhance united states europeroche competitiveness ofthese product develop fuzeon partnership trimeristhe european summer finding phase authority grant fuzeon iii trial show new hiv fast track review statuswe expect pharmaceuticalse positive decision filing product condition early production offuzeon strict prescribing rule extremely complexand manufac apply manufacturer ture facility work require institute patient safety clock ensure supply programme similar roche available great possible number ofpatient product sale ofxenicalthe world lead isapproved medicine weight loss weight controlwere line influenza medicinetamifluis overall decline market seg available worldwidefollowe mentdata submit regulator approval summer european halfof role union treatment preven xenical treat overweight patient tion ofinfluenza bwhile sale nearly doubledthey amount relatively modest million swiss francsowing year mild flu season northern southern hemisphere key product sale rocephin slightly previous yeardeclining result ofgeneric erosion europe year relatively low influenza activity year market rocephin remain injectable antibiotic ofchoicethank high undiminishe efficacythis prod uct post sale ofover bil lion swiss franc sale ofroaccutaneaccutaneour type diabete lead label medicine severe acnedecrease change european union million swiss francsthe approval ofthe medicine type decline primarily tight diabete canada australia prescribing restriction united recentlydata landmark trial statesoverallhoweversale xendosdemonstrate weight loss well expectedalthough roac regimen combine xenical cutaneaccutane go offpatent andlifestyle change significantly unite statesits big marketin well lifestyle change februaryit face competi inprevente type diabete tion generic late second halfofthe yearin novem dilatrend post sale million ber december fda grant swiss francsa doubledigit increase licence generic version ofthe previous yearapproval pharmaceutical market product chronic heart nership glaxosmithklineroche failure japan severe chronic planning market novel oral heart failure europe strength intravenous formulation ene dilatrends position seg offer benefit patient mentfinding major study physiciansapplication file show start patient early european approval treatment dilatrend tomarket ibandronate postmeno ace inhibitor significantly pausal osteoporosis improve clinical outcome mild tomoderate heart failure roche consumer health sale ofnonprescription medicine clinical development ofibandronate otc businessroche consumer ahighly effective bisphosphonate health rchdecline local treatment prevention ofosteo currency swiss franc porosisis move ahead wellin million swiss franc weak sale ofaleve latin americas currency problemsparticu larly devaluation ofthe argen tinian pesowere factor hamper ing growth yearsale ofaleve united stateswhere brand market joint venture bayerwere latin america unable offset effect offalle currency despite price adjustment marketssale market account ofour busi nessgrew rate factorscouple building strong competitive strong swiss franchad negative impact operating profitwhich brand create lasting value decline million swiss ability develop francsebitda decrease million swiss franc brand equips respond roche consumer health key difficult challenge face brandsposte good growththe market exception redoxonwhich gener ate halfofits sales latin richard laube head roche consumer health america pharmaceuticalsresearch development consumer selfmedication substantial number new product expect medium term roche research base distinctive inno vation model clear speciality skin care strategy partnership play analgesic gastrointestinal product key roleapart roche cold remedy powerful inhouse research organisa sale therapeutic area tionthe pharmaceutical division network include genentech vitamin chugaiwhich function largely independent research satellitesin additionroche optin right programme ofexternal devel opment organisation create bioxellset basilea pharmaceuticathis lead otc brand source ofpromise compound change sale local pipeline product use million chf currency aleve naproxen analgesic agreement conclude supradyn multivitamin company yearroche bepanthen skin care rank industry leader rennie antacid term oflicense redoxon vitamin roche currently january pursue pharmaceutical research project inhousein new molecular entity nme enter phase enter phase opment increase significantly clinical testingthe pharmaceutical past yearsthe seam division currently nme process estab development pipelinethis include lishe recent year promote well optin opportunity potential decisionmake contribute new medicine genentech create great future value develop chugai project roche hasthe right licensein ongoing initiative concentrate anyproject chugai seek optimise productivity apartner outside japan south focus value gen korea erated project quan tityprogress achieve increase number ofpromise implement number oftool nme compare result compound selection profiling ofstructural adjustment phar early research stagethese maceutical organisationthe harmonise research number ofproject phase devel centre pharmaceutical pharmaceutical network include numerous alliance col laboration major industry science institution globe example partnership decode geneticswhich year lead identification ofthirteen genetic risk factor common diseasesinclude stroke rheumatoid arthritis schizophre niaas result ofthese discovery roche pharmaceutical research investigate new drug targetssuch glucokinase activator innovative way manage treatment ofdiabetesin roche decode enter research activity roche new threeyear alliance group allow exploit synergies outlook roche expect pharma generate competitive knowledge ceutical division organic growth ultimately create medicine enhance launch ofpegasys fuzeonour oncology diagnostic product provide great business continue strong growth trend thank key prod benefit patient uct mabtherarituxanxeloda herceptinneorecormon cell jonathan knowles head research cept remain growth driver anticipate establish product rocephin roaccutane research project accutane remain important major therapeutic area january revenue earner lose current prominence generic erosion metabolic disorder virology year roche plan oncology vascular disease file new drug application urogenital disease key therapeutic area oncology inflammatory disease hivaid anxietydepression central nervous system weintend additionally strengthen portfolio continue inten sive inlicensing activity pharmaceutical division look outperform global marketwith division strong pharmaceuticalsdelif enilepip dednapxe yllaitnatsbus noitacidni iii esahp esahp esahp esahp noisnetxe enil rojam eman cireneg epyt tcudorptcejorp aera cituepareht aimena detalerrecnac aimena laner tnemtaert aimena noitareneg txen aimena aimena tnemtaert aimena yparehtoidar ateb niteope nietorpocylg nomroceroen sisoropoetso noitneverp dna tnemtaert etanordnabi etanohpsohpsib etanordnabir enobnoitammalfni sitirhtra diotamuehr rotibihni esanik sitirhtra diotamuehr rotibihni esanik sitirhtra diotamuehr bamixutir ydobitna lanolconom arehtbam setebaid epyt rotibihni emyzne msilobatem setebaid epyt rotaludom rotpecer raelcun setebaid epyt rotaludom emyzne setebaid epyt rezitisne nilusni anapaj tnempoleve tatsilro rotibihni esapil lacinex noitacidni tnecseloda setebaid noitneverp yteixna dna noisserpe rotaludom rcpg metsys suovren noisserpe rotaludom rcpg yteixna dna noisserpe rotaludom rcpg esaesid sremiehzla rotibihni emyzne sruomut dilo enolihtope rotibihni emyzne ygolocno siseme rotaludom rcpg siseme rotaludom rcpg sruomut dilos bamuzutrep ydobitna lanolconom sruomut dilos rotibihni emyzne sruomut dilos rotibihni emyzne recnac nairavo bamomutmep ydobitna lanolconom recnac tsaerb ydobitna lanolconom sruomut dilos nacetomolfid rotibihni emyzne sruomut dilos rotibihni emyzne sruomut dilos binitolre rotibihni esanik avecratr recnac tsaerb esaesid enob citatsatem etanordnabi etanohpsohpsib tanordnob recnac tsaerb tnemtaert tnavujda bamuzutsart ydobitna lanolconom nitpecreh aimekuel citycohpmyl cinorhc bamixutir ydobitna lanolconom arehtbam noitanibmoc citatsatem dna tnavujda enibaticepac adolex recnac noloc tnemtaert recnac tsaerb tnavujda amhtsa tsinogatna nirgetni yrotaripser amesyhpme tsinoga rotpecer raelcun amhtsa tsinogatna nirgetni noitcejer tnalpsnart laner etuca rotibihni nirueniclac tnalpsnart noitcefni surivolagemotyc noitneverp rivolcicnaglav eugolana edisoelcun etyclav noitatnalpsnart nagro dilos ytivitisnesrepyh civlep reddalb evitcarevo tsinogatna rcpg ygoloru ecnenitnocni yraniru dexim dna ssert rotaludom rcpg ecnenitnocni yraniru ssert rotaludom rcpg ytivitisnesrepyh civlep reddalb evitcarevo tsinogatnarcpg noitcefni vih rotibihni esaetorp ygoloriv noitcefni vih rotibihni esatpircsnart esrever edisoelcunnon sititapeh rotibihni esaremylop eugolana edisoelcun noitareneg wen sititapeh gurdorp nirivovel strawlatineg nietorpnoisuf noitcefni vih editrivufne rotibihni noisuf noezuft noitcefni vih rotibihni noisuf sititapeh nirivovel eugolana edisoelcun noitareneg wen nirivovelr noitalumrof cirtaidep rivaniuqas rotibihni esaetorp esavotrof sititapeh cinorhc aafla norefretnigep norefretni detalygep sysagep noitalumrof wen noitcefni vih etalysem rivaniflen rotibihni esaetorp tpecariv bhcetneneg hguorht noitapicitrap ydobitna nlm esaesid lewob yrotammalfni ydobitna lanolconom ydobitna pdl remrof emordny yranoroc etuca tnemgarf ydobitna lanolconom baf yparehtomehc htiw sruomut dilos nitsava ydobitna fgevitna nitsava noitarenege ralucam detalerega tnemgarf ydobitna lanolconom baf dma sisairosp bamuzilafe ydobitna adcitna milenax yllamrof avitpar sitirhtra diotamuehr amhtsa bamuzilamo ydobitna egiitna rialox biaguhc hguorht noitapicitrap amoleym elpitlum ydobitna lanolconom mha sisoropoetso enomroh dioryhtarap tnanibmocer shc recnac tsaerb lxt etamatulgylop chc sesatsatem enob ydobitna lanolconom lac sisoropoetso evitavire nimativ esaesid traeh yranoroc tnadixoitna siseraportsag tsinoga nilitom ymotcetapeh tsop rotareneger revil lav egahrromeh dionhcarabus savetna sitirhtra diotamuehr ydobitna lanolconom arm nemow lasuaponemtsop sisoropoetso lch enefixolar atsive aimetahpsohprepyh lch remaleve leganer nemow lasuaponemtsop recnac tsaerb elozortel aramef cseitinutroppo nitpo sruomut dilos tnega gnitegrat ralucsav aaxmd amositna recnac gnul llec llamsnon tnemgarf ydobitna lanolconom bafareht egahrromeh dionhcarabus tsinogatna rotpecer nilehtodne vxa navoxa sisairosp rotaludom rotpecer raelcun lab acituecamrahp aelisab amezce dnah cinorhc dica cionitersic lab noitcefni lairetcab citoibitna lab noitcefni lagnuf lagnufitna lab noitcefni lagnuf lagnufitna lab esaesid ralucsavoidrac tsinogatna rotpecer nilehtodne pps ledeeps era eseht enilepip tnempoleve snoisivid slacituecamrahp eht semn yltnerruc era ereht ton yam stcejorp emos snosaer evititepmoc rof srentrap lanretxe dna esahp era gnitset lacinilc esahp deretne evah esahp tnempoleve egatsylrae deifitnedi neeb evah akinhcetosi secneic nohpyrg delifiii esahp noitadilosnoc lluf rividem etutitsni sciteneg tcudorp eht esnecil thgir eht sniater ehcor nci enilkhtimsoxalg tnempoleve lacinilc lacinilcerp morf noitisnart esahp negssert cedihcetneneg sreetnulov yhtlaeh seiduts laitini esahp siremirt slacituecamrahp yromem stneitap seidut gnidnifesod dna ytilibarelot ycaciffe elacsllams esahp noruoga secneicsoib nasok ycaciffe dna ytefas noitamrifnoc lacitsitat rof stneitap seidut elacsegral iii esahp semn seititne ralucelom wen stneserper epyteulb yllil ile hcetneneg yraunaj tnerruc yrewerb nirikemyzneg amositna sitravon nespi ruofuaeb isohcetneneg oncology portfoliothe rollout pegasys fuzeon integra tion ofchugai expect fuel solid doubledigit growthwe anticipate synergies result integration ofchugai effect division remain committed raise operate profit margin year pharmaceutical christian artificial heart valve take anticoagulant effect monitor reg ularly blood test roche coaguchek device enable patient monitor coagulation status suit christians active lifestyle perfectly small christian provide reliable information vital health tool network organise analyse datum increasingly demand kind healthcare setting laboratorie hospital patient selftesting challenge translate raw datum actionable healthcare information major task address diagnostic divisiondiagnostic division brief change change local million chf chf currency sale diabetes care near patient testing centralized diagnostic molecular diagnostic apply science ebitda operating profit expenditure employee diagnostic diagnostic division extend global market leadership sale business area grow ahead market division geographic regionsa gain market share increase prof itability addition systematic customer focus market development number strategic initiative reshape expand division make supplier diagnostic test system provider actionable health information help deliver strong performance research devel opment alliance license internal venture project key component help drive process forward diagnostic market ofthe division busi ness areascontinue aboveaverage gain diabetes care molecular diagnostic reflect innovative strength focus market develop ment activity ofthese business areasin roche diagnostic fur ther strengthen position world lead invitro diagnostic companyexpande global market share compare divisional profitability increase operate profit million swiss franc ebitda advance million swiss francsthe division operate profit ebitda margin respectivelyan increase percentage pointsincrease expenditureparticularly research industry leader continue development license activi play responsible active role tieswas offset strong sale growth help shape market goal doctor patient healthcare sale outpace market growth region sale grow ahead payer optimal access reliable informa market ofthe region serve divisioncontinue tion support enable timely growth north america drive effective decisionmakingat mainly diabete monitor businessmolecular diagnostic prod time critical grow fast uct elecsys immunochemistry market product linein europe dynamic growth see continuedwith heino von prondzynski head diagnostic division important contribution result increase harmonisation ofana lytical platform reagent clinical laboratoriesthe doubledigit market leadership extend sale gain record big diagnostic division region surpassedonce total million swiss francsa injapan asiapacificsale yearonyear increase local iberialatin america suffer currencies swiss franc result ofthe continue economic againsale grow fast crisis latin america diagnosticshelpe shape future roche isplaye active role shape tomorrow invitro diagnostic mar ketto meet need actionable health informationroche develop ing solution combine cut edge diagnostic information management connectivitythe aim linkorganise translate diagnostic datum information support enhance clinical deci sionmakingthe division begin create infrastructure need serve young fast grow market secure access necessary technology mellibasean online service package diagnostic sale millions chf launch mar ketsis example ofactionable health information rocheuse mellibasedoctor health insurer provide diabetes patient individualisedevidencebase infor mation potential medical complication economic conse quence oftheir conditionexplain treatment option motivate patient adhere optimise treatment routine division active licensing policy creativityskill entrepreneurial continue play strategic roleby initiative inter grant licence intellectual prop national organisationdesigne erty underpin exist busi identify mobilise untapped talent nessroche promote wide use ideasthe initiative far lead associate technology system evaluation ofseveral thousand apply particularly pcrin business proposalsfocuse pro additionby acquire licence ject likely result new health information area product open new market division move secure opportunitiesfour ofthese compa innovative strength future ny companyare generate revenue year thank internal venture process establish initiate roche diagnostic succeed bring diagnostic strong growth business area ficial pancreas use diabetes diabete care thank contin patientsone ofroche longterm ued success ofthe accuchek product goalsthe system long linediabete care extend monitoring capability market lead blood glucose monitor accuchek monitor schedule ing segmentposte local currency initial launch germany growth ofonce againthe accu market medical chek advantage glucose meter professional use mainly clinical ofthe main growth driverssuc trial asiapacific japan near patient testing apply science europe molecular diagnostic sale region sale business area north america diabetes care centralize diagnostic iberialatin america cessful launch europe japan introduction ofa new test strip continue global rollout ofaccu accuchek compact glucose chek compactthe glucose meter meter schedule giving feature integrate test strip fast result bloodit automatic check ofstrip integrity selfmonitore ofblood glucose easiera secondgeneration ver global rollout ofaccuchek active sion ofthe accuchek compact extremely lightweightuserfriendly include integrate lanc glucose meter provide test result e systemis currently develop secondswas successfully complete mentthis innovation help lead position fast second quarter see fda grow integrate spot monitor approval ofaccuchek pocket com segment glucose meter combine passa software design personal test stripsautomatic check ofstrip digital assistant enable data integrity lancing system download directly blood glucose meter february roche announce itsintention acquire medical accuchek monitora continuous device supplier disetronicthe world blood glucose monitoring system secondbigg maker ofinsulin take reading minute pumpsthis enable roche daysmark major milestone offer comprehensive solution development ofan arti diabetes management cover diagnosticsthe glucose selfmonitore individualised insulin delivery late insulin pump technology propose acquisition subject approval disetronic shareholder vote roche offer special general meetingand trans action clear antitrust authority near patient testing sale roche near patient testingwhich supply product service doctor officesambulance intensive care unitswere local currency confirm business area market leadership omni ofthe main yearscontinuous market devel revenue earner segmentroche opment near patient test diagnostic hope duplicate ing lead supplier coagula success launch tion monitor segmentthe trend omni new multiple parameter selfmonitore ofcoagula blood gas analyser tion status patient continue result substantial sale mar increase demand infor ket share growth coaguchek mation extensively networked product line grow accept rapidly available ance ofcoagulation selfmonitore neededaccordinglyroche diagnos test health insurer increase ticsstrategy ofpackaging system prescribe oforal anticoagulant global solution combination reason development product datacare roche technological leadership positive impact area underscore sale launch ofa newimprove teststripscheduled primary care segment compact system doctorsoffice roche sale hospital point ofcare confirm leadership mar unitwhich supply rapid diagnostic ket pointofcare urinalysis product emergency room multiparameter system intensive care unitsgrew twice reflotron product lineroche diag fast marketthis good nostic plan special web portal formance drive primarily sale direct communication cus ofcardiac assay ofomni tomersthis physician new analyser measure ofthe pathologist access information important critical care param andservice relate division etersin year market primarycare product diagnostic researcher patient broad range diagnostic product market research market healthcare provider consumer apply science reagent innovative system research labs service lab patient technologies medical biotech university hospital hospital consumer research food safety testing doctor office biochemical reagent industry gps molecular diagnostic apply science pcrbase test analyser lightcycler magna pure diagnosisidentifye disease predis rapid translation system position monitoring disease rt proteoexpert reagent progression response therapy research industry molecular diagnostic centralize diagnostic cobas amplicor cobas ampliprep integrate solution vitro diag cobas taqman cobas ampliscreen nostic laboratoriesinclude thing analyser test reagent intelligent workflow optimisation centralize diagnostic service offeringsinnovative diag modular analytic swa rochehitachi nostic parameter system use cobas integra elecsys cobas core stago sysmex elecsys probnp laboratory diagnostic near patient testing near patient testing coaguchek cardiac reader product service pointof troponin omni reflotron care testingincluding coagulation combur test chemstrip monitoringelectrolyte blood gas accutrend gct datacare analysisrapid urinalysisclinical diabetes care chemistry analyserssystem rapid accuchek product line accu test cardiac markersinformation chek compact accuchek management connectivity soft sensoradvantage accuchek ware active softclix diabetes care division centralize diagnostic molecu innovative blood glucose monitor lar diagnostic near patient testing business serve need health systemsservice information professional link forpatient diabete health labnetwork organisation professional involve diabetes management diagnosticscentralize diagnostic sale test detect disease centralized diagnostic unitthe lead help doctor determine ing supplier ofintegrate analytical severity likely prognosis system hospital highvolume thank probnpheart failure laboratoriesadvance local detect early stage currenciesoutpace market treatment significantly improve asubstantial marginthe increase nearly million symp wasdriven primarily elecsys tomatic heart failure patient immunochemistry integra united states aloneand roughly clinical chemistry product line halfamillion new case diagnose hematology product market year north america number european asian country japanese partner sysmex roche presence segment hasbeen strengthen global rollout ofmodular analytic swathe commercially available serum work area combine high throughput clinical chemistry immunoassay test single plat formthe platform configure individual laboratoriesneed iscapable ofprocesse roughly patient sample single passthus set new standard ofefficiency productivity wide range ofhighquality test roche lodge appeal available modular analytic swa judgement issue igen lawsuit isanother reason system april low court hasreceive positive market united statesat time responsein menu discussion igen aim expand include test hor ofestablishe successful basis monescardiac marker marker future cooperation benefit ofbone metabolismthis bring party number ofclinical parameter determine molecular diagnostic roche elecsys analyser molecular diagnosticsthe market leader fieldposte sale year see successful launch increase local currenciesa growth ofelecsys probnpthe commer rate ahead cialfullyautomate test diagnos market averagethe business area e heart failure monitor ampliscreen test screen patientsresponse treatmentthe donate blood blood product diagnostic test hepatitis donor blood japanthe nether sexually transmit disease deliver land united kingdom especially robust growth broad portfolio ofhuman papillo gain business area reflect mavirus hpv patent acquire strong demand product base institut pasteur give solid onthe highly sensitive polymerase basis develop marketing chain reaction pcr techniqueusing product early detection pcr technologyit possible copy hpv infectionhpv lead specific segment ofgenetic material cause ofcervical cancera disease millions oftime overinclude early diagnosis treatment tiniest fragment ofbacterial critical positive prognosis viral dnapcrbase test afford late plan market mean ofdiagnose number hpv test expect supplant condition rapidly reliably conventional pap smear test mid term agreement like sign unparalleled product pipeline institut pasteur estab lishe strategic alliance qiagen develop commercialise inte grate nucleic acid diagnostic system diabetes care carefully target reinforce near patient testing apply science leadership molecular diagnos business area expect contribute tic major innovation year molecular diagnostic centralized diagnostic january roche diagnostic affymetrix sign agreement grant roche nonexclusive right affymetrixs array instrument follow successful launch technologies yearsone number ofmarketsa new version ofthe benefit ofhaving access highly sensitive amplicor hiv genechip technology test clear united states enable develop specific diagnos inmid use monitor tic laboratory test wide range patientsresponse aid therapy ofdiseaseswe confident synergies affymetrixs december fda genechip platform roche pcr grant regulatory clearance technology establish new standard cobas ampliscreen systemfurther genetic testingmaking possible strengthen position tailor therapy individual patient blood screen sectorfda approval profilesand enhance ofroches pcrbase hepatitis roche diagnosticsattractiveness hiv test design use apartner company working system follow later month development ofmarker guide roche test screen individualised therapy diagnosticsthe global rollout ofcobas taqman fully automate pcr analyser isprogresse scheduleit big brothercobas taqmanwa success fully launch united states january cobas ampliprep sample preparation sys temthese analyser represent milestone ongoing effort develop market new medical application pcr blood screeninghpv test woman test sepsis blood poisoning expect stimulate additional growth business areaas new pcrbase product use foodborne pathogen salmonella genomic listeria ofgenetically modify food constituent apply science roche apply sciencewhich make reagent new range ofresearch test hightech systems scientific codevelope innogenetic industrial researchrecorde sale detection ofdangerous bacteriaan growth local currency important step road com maintain position year prehensive portfolio ofdirect assay particularly challenge biotech busi microbial pathogen blood ness environmentthis strong formance drive sale ofthe rapid translation system rt magna pure lightcycler pcr worlds commercial system workflow system primarily cellfree protein expressionroche fur genetic research genebase diag ther extended rts product range nosticslightcycler instrument launch ofthe rt amplify genetic material proteomastera highly versatile system dna analysismagna pure wide range ofapplication module automates pcr sample proteomic preparation entry field ofscien apply science tific service roche apply science successful effort expand isseeke develop completely new new marketsone example market segmentproteoexpert collaboration begin autumn aninternetbase information service idexx laboratories usa veteri design help scientist work nary diagnosticsanother exten rt achieve fastermore sion ofour range ofproduct food efficient protein synthesisit testingnew lightcyclerbase test develop cooperation biomax enable rapidprecise detection ofthe informatic ofgermany diagnostic launch ofadditional product connectivity order strengthen service expect market lead remain industry strengthen apply sciences market trendsetterroche diagnostic ide positionthese include system ally position continue active produce customise biochip use role shape invitro diagnostic researchan expand version ofthe market ofthe future lightcyclerthe new indycycler pcr instrumentand new service result ofan internal venture project offer synthesis ofspecial protein industrial client outlookthe division excellent formance confirma tion pursue correct strategy realignment initiate year agofor expect thatdivisional sale continue advance ahead ofthe market weremain confident ofachieving operating profit margin ofslightly well expect dynamic sale growthparticularly europethe united statesasiapacific japan medium term intend strengthen market leadership launch ofinnovative new product continue pursue pronged success strategy drive strong commitment invest absolute term competitorsour internal venture process provide source ofnew business modelsproduct s vicesand network ofalliance lead technology company continue systematically evolve division provider actionable health information target strategic initiativesin par ticularwe focus improvement innovation area hos pital information management diagnosticsvitamin fine chemical division brief change change local million chf chf currency sale vitamin carotenoid fine chemical ebitda operating profit expenditure employee charge vitamin case impairment division net asset vitamin fine chemical february roche announce intention div vitamin fine chemical division order concentrate fully core pharmaceutical diagnostic business month later group disclose plan sell division dsm netherlands contract finalise february actual closing date depend soon authority approve sale economic condition remain difficult vitamin fine chemical division hold market share post substantial volume gain vitamin fine chemical currency increase second half ofoperating profit charge vitamin case impairment ofthe division net asset decline million swiss franc ebitda million swiss francsthe division operate ebitda margin respectivelyamong factor contribute weak performance unfavourable exchange rate ofthe dollar relative swiss francrestructuring onetime cost low price product volume ofproduct sell division rise substantial especially strong gain record new productsgrowth ani mal nutrition segment lead division hyd feed supplement aggressively continue enzyme product robust volume strategy develop commer gain post food seg ment naturalsource vitamin cialise new well product polyunsaturate fatty acid new carotenoid lycopenelutein deliver differentiate benefit zeaxanthinin fiercely competitive customersthis strong cosmetic segment division score major sale success stable position extend global market vitamin formulation stayc lead parasol slxa newgeneration uvb sunscreen launch year markus altwegg head vitamin fine chemical division vitamin cthe bcom plex vitamin product global market leader step experience significant pricing pre volume growth vitamin suresthe division take step offset fine chemical division record sale impact ofprice erosion imple ofalmost billion swiss franc mente additional programme compare previous restructure manufacturing opera yearthis equivalent increase tion marketing infrastructure local currency decline inswiss francsalthough north america division con year anticipate market upturn tinued gain market sharedespite occursale growth local downward pressure pricesthe vitamin fine chemicalsdivision outperform expectation fermentation process fully way sale dsmafter swiftly complete regionrecorde yearonyear process live upto preparationsannounce spring volume gain increase sale division high expectationsfollowe div vitamin fine local currenciesin europe nega startup difficultiesthe newbiotin chemical divisionroche decide tive trend note early year plant grenzach able meet august sell division reversedby contrastthe situation increase demand vitamin netherlandsbase dsm groupas latin american market remain midyearprice adversely core business ofdsm chemical critical ofthe region cur affect second halfof company strong life science rency problemsthe division overall howeveras supply exceed demand focus division share ofthe astaxanthin market neverthelessbiotin sale signifi solidly position extend market remain stabledespite downturn cantly well production technology leadership demand chile salmonfarme ofvitamin year benefit new opportunity sector sale growth especially asa result ofdelay construction growththe division remain firmly positive highpotential chinese work vitamin plant dalry committed pursue plan marketthe division post substan scotland objectivesall ongoing capital expendi tial growth local currency term ture restructuring project asiapacific region forexamplewill implement asiapacific food cosmetic pharmaceutical sale region sale customer segment europe africa animal feed north latin america strategic investment production division continue focus plannedany residual liability relat research vitamin fine research effort develop innova ing vitamin case remain chemical division reinforce lead tive new product efficient roche groupnegotiation premix supplier open new manufacturing processesin dsm finalise contract stateoftheart plant feed pre design support divi successfully conclude february mix chilehungary vietnam sion initiativeaime food premix china reduce cost year south africa anew biotech centre open brand vitamin product successful year division pre grenzachprogress initiative supradynberocca redoxon mix business trackdivisional research unit continue market roche develop number ofnew formula consumer healthour nonprescrip construction work world tionsincreasing level ofdiffer tion medicine businessand advanced vitamin manufactur entiation exist product line ofthis transaction ing facility proceeding sche steppedup effort drive innovation ulein sisseln switzerlandat reflect number ofnew grenzach germany site production patent application filedwhich dou ofvitamin industrial bleed compare vitamin fine chemical roche support phelophepa health train clinic rail bring affordable primary health service people live rural area south africa roche provide operating funding roche health clinic staff visit area school train stop educate people health issue raise public aware ness specific problem year people treat phelophepa health train provide general medical service dental eye care psychological counselling phelophepa project aim help people help volunteer commu nity visit train attend basic health education course act multiplier pass learn othersin communitiespeople environment human resource safety environmental protection social involvement distinct area common concern people year introduce roche connect work roche chance share financially company successand continue promote corporate culture reward performance ongoing effort enhance safety environmental protection result reduction energy consumption emission harmful pollutant benefit employee communitie roche facility locate remain actively involve effort overcome critical lack healthcare affect people develop country people environment human resource healthy growth lead rise headcount healthy sale growth post division lead toselective affiliate staffing increase year end roche group employ people countriesthe diagnostic division recruit new employeespri marily europe north america pharmaceuticals division headcount mainly result new hire united stateslatin america eastern europethe con solidation ofchugai contribute establish culture reward rise division headcount increase number ofemployee performance promote entrepreneurial injapan end thinking level organisation total headcount increase figure roche connect employee equity plan resultthe cost ofwagessalarie opportunity employee share employee benefit rise million swiss franc directly roche success equity ownership programme daniel villiger head corporate service promote employee identification roche new programme call roche connect launch aim ofgive employee human resourcesworldwide opportunity pur headcount division year end chase roche nonvoting equity securi change change tie genussscheine discount pharmaceutical participate group success diagnostic end offebruary vitamin fine chemical programme introduce countriesaround ofthe employ roche group ee country sign roche connect farthe pro headcount region year end gramme schedule rollout europe country switzerland north america see launch ofa new latin america nonvoting equity security option pro asia gramme highlevel employeesas japan group buy underlying securi africa australia oceania tie equity instrument total stock marketthere nodilution ofthe value ofroche security add value performance performancebase compensation ued activity enhance system introduce year ago leadership competency remain progressively extendedwith high priority division financial incentive manager considerable progress link closely contri develop compensation incen bution increase company tive programme reward outstand valueone component value ing achievement orient performance management system introduce key human resource focus bedeveloped diagnostic division year formulation ofleadership principle pharmaceutical division divisional manager base human resource activity roche corporate leadership philoso focus establish sus phythese implement tainable leadership performance ofthe remuneration culturethis support manager eligible variable compen anexpande global human resource sation package relate function divisionfrom closely goal achievement talent identification leadership performance leadership development base global standard expand roche global human resource initiative rollout ofour executive develop intensify talent development ment programme collaboration junior leadership process london business school contin launch ofan assessment develop human resource ment centre manager advance stage oftheir careersthese com plemente global learning development programme individ ual team support successful implementation ofroche business strategy dsm acquire vitamin fine chemical division february roche sign contract sell itsvitamin fine chemical divi sion netherlandsbase dsm groupthe transaction subject approval antitrust authority expect close sale firsthalfofdsm agree honour current term condi tion ofemployment ofthe division employee provide postretire ment benefit health coverage atcurrent level higherongoe restructure programme division complete plan human resourcessafety environmental protection sustainability safety environman tal protection crucial issue rochea continuous demonstra ble advance area genuine measurable contribution sustainable developmentroche firmly believe sustainable busi ness practice key success forwardlookinginnovative com pany decade steadily reduce emission theairwater soilin recent year regard effort behalf achieve mainly improve exist manufacturing safety environmental protection process replace fundamentally new one ecoefficiency sustainability theadditional advantage ofreduce merely obligation energy consumption waste volume society parcel corporate activity roche systematically implement corporate healthsafety han knzi head corporate safety environmental protection environmental protection standard business charter sustainable development develop inter energy consumption associate national chamber ofcommerce emission implement guideline formulate chem process optimisation ical industry worldwide responsible care programmein particularwe contribution sustain subscribe precautionary princi able development gain ple principle ofecoefficiency number ofhonoursinclude award san francisco bay area accordinglywe remain committed business environmental network increase ecoefficiency ofour forroche palo alto california manufacturing operation reduce usa energy reduction safety environmental protection safety environmental protection expenditure millions chf environmental stewardship roche ofthe swiss firm investment continuously participate interna operating cost tional programme safe man total expenditure agement ofchemical oecdicca ceficthe aim ofthese programme evaluate environmental impact improve knowledge environmental programmesand environmental protection group substance worldwide large clean industry award wide energy conservation effort con quantitiesroche major con facility cuernavacamexicoin tinue successfully year tributor international chemical additionseveral roche facility gain reviewsupporte variety ofcam industry long range research initia iso certification paignsenergy consumption tivewhich investigate impact reduce substantial oftrace amount ofchemical healthsafety environmental humansanimals environment protection expenditure come additiona special campaign support national research pro million swiss francsor launch reduce emissionsin ject similar objective ofsalesthe increase primarily accordance agreement reach new environmental protection environmental conference rio concern rocheas equipment new production facili kyoto johannesburgroche member ofvarious national tie integrate control intend decrease emission international bodiesha follow greenhouse gas ing eus deliberation strat accident incident active contribution reduc egy future chemical policyin previous yearsthere major ing climate changein cam february european commis incidents group facility paign result decrease sion publish white paper contain number ofincident emission ing proposal new european legis decline yearearli level lation chemicalsinitial draft severity frequency group goal elimina legally bind regula accident decline significantly tion ofhalogenate hydrocarbon com tion directive expect comparison positive pound cool system fire spring propose new regis result toour uncompromise extinguishersby steadily replace tration procedurebroad interpreta commitment training develop halogenate hydrocarbon tion ofthe precautionary principle ment ofse officers agent alternative technical solu additional bureaucratic hurdle employeesin training focus tionsroche work help protect seriously jeopardise europe risk managementrisk analysis ozone layer reduce green attractiveness centre incident management aspect house effectin effort lead chemical pharmaceutical industry occupational medicine reduction total inventory ofhalogenate hydro total audits con carbon roche facility ducte countriesthe visit confirm high safety emission ofvolatile organic com health environmental protection pound voc roche plant standard maintain group reduce overall facility past yearsin voc emission cut comparison safety environmental protectionsocial involvement face good corporate citizenship global company roche contribute daily improve quality oflife ofpeople theworldwe directly involve community service projectsmake donation charitable cause work partnership wide range ofnonprofit organisationsat roche good corporate citizenship extend environmental protection promote public health awareness education provide humani tarian aid innovation central roche look innovative way pharmaceutical diagnostic improve healthcare delivery devel oping countriesbecause ofthe close research break alignment diagnostic new ground resolve healthcare therapeutic businesseswe able contribute effective use challenge develop world ofthese countriesvery limit far insur resources mountable train hope assure access basic medical carerelieving franz humer chairman board director ceo heavy burden ofdisease develop country require sweep improve social involvement phelophepa health train fact figure ofit lead sponsorsat cere health train begin operate consist coach mony roche hon today boast coach weigh tonne fully equip provide oure awardpresente general medical service dental eye psychiatric care south african cabinet ministerfor phelophepa spend week year travel country permanent staff itscontribution health train work student prepare career variety medical healthrelate field return day volunteer service student gain coach housing train valuable practical experience people treat train health clinic officially rename year far health train bring basic medical service roche health clinicin recognition million people remote part south africa roche longstanding continue train annual stop member local community supportroche assume finan come aboard fiveday course provide basic information subject cial responsibility clinic aid hygiene infectious disease sound nutrition family health provide funding maintenance method help people help bring significant salariesmedical equipmentconsum last improvement health people living region visit train able training materialssince phelophepa contribute sustainable development rural south africa roche contribut ingto initial inservice training activity help clinic staffstay ment infrastructureor creat abreast ofnew advance primary ing infrastructure care provide well possible existsfor startthis mean address service e basic need sound nutrition clean waterand involve build united hiv provide access good primary care partnership international raise awareness ofhealth problem organisation unaid create institutional national governmentsrelieforganisa resource need provide spe tion industry critical role cialist treatmentnobody meet play combat hivaid challenge alonebut thethird worldas founder member broad coalition ofpartner work ofthe accelerate access initiative togethersignificant progress possi bring blesouth africas phelophepa project unagencie researchbase impressive example ofjust pharmaceutical companiesroche achieve support effort phelophepa whichtranslate liter important step take allymeans goodclean medical care recently ensure broad access ofa mobile clinic rail treatment hivaidsgovern possible alliance ofhealth ment actively care transport companiesgovern involve fight aids ment agency universitiesthe time recognise project deliver basic medical service obligation impose international large number ofpeople remote trade patent lawspharmaceutical rural area ofsouth africaroche companiesfor parthave support train ofhopea major concession drug pricing local people itsince roche position matter clear social involvementwe intend profit aid drug africamoreoverwe refrain submit patent application assert exist patent right antihiv product develop country country subsaharan africa classify develop develop countriesand particu larly subsaharan africawe supply major drug invirase vira cept term favourable offer manufacturer genericsin case ofviraceptwe tific medical expertisethere able reduce price plan expand initiative future sharply thank improve help ofdonor fundingcare ment manufacturing process serve model important therapeutic agent organisationshiv project africa additionroche diagnostic sup ply highly sensitive pcr test diagnose hiv monitor antiretroviral therapy massively reduced price important measure fight hivaid low price solve problem affordability ofmany barrier healthcare develop nationsroche support project promote prevention andhelp improve infrastructure carea pilot project initiate early conjunction pharmaccess international facilitate access hiv treatment kenyaugandacte divoire senegali success fully underwayinfrastructure dis tribution problem cause initial delay ofalmost year get project offthe groundroche funds pilot projectin addition sup port medicinesdiagnostic kitseducation programme scien social involvement finance year great change roche groupsignificant step havebeen take strategic objective create unique healthcare company focus hightech pillar pharmaceutical diagnostic vitamin fine chemical division long consider core activity consequently divest dutch group dsmin october alliance chugai completedimprove roche presence world second large pharmaceutical market quantum leap underlie core business pharmaceutical diagnostic continue achieve improved operating result strong cash generationthese positive development overshadow factorsan impairment charge cause divestiture vitamin fine chemical businesssignifi litigation expense impact set new basis manage ment equity portfoliofor year active management roche liquid fund longterm investor perspective major contri bution net incomesince downturn world equity market roche incur substantial unrealised loss onit financial assetsthese unrealised loss consistently report roche balance sheet byproactively revise accounting policy line expect development ifrsroche create renew financial flexibilitythe relate onetime impairment open way manage liquid asset objective generate financial incomereduce debt invest strategic development core business impact factor result report net loss billion swiss francsgoe forward roche solely focus successful profitable cashgenerating core businesseswhich generate anet income billion swiss franc financefinancial review highlight millions chf figure report figure report financial statement adjust basisa change change sale ebitdab operating profit net income adjust figure internal management roche group represent result thegroup underlie ongoing operation exclude special item include continue business page description reconciliation ebitda earning interest financial income tax depreciation amortisation include impairment correspond operate profit depreciation amortisation including impairment core pharmaceutical diagnostic business deliver good result show adjust result pharmaceutical deliver particularly strong result oncology transplantation area addition generic competition roaccutaneaccutane theunite state come later expect result include month worth result chugai diagnostic show continued growth business area especially diabetes care financial impact reposition roche group certain litigation matter huge impact report result litigation cost vitamin case genentech legal case total billion swiss franc book value net asset vitamin fine chemical division writtendown billion swiss franc base sale price agree dsm partly offset book gain billion swiss franc disposal nippon roche single large impact respect financial asset fall world market year particularly month result net unrealised loss billion swiss franc group equity portfolio con sistent ongoing restructure group finance treasury operation group decide proactively revise accounting policy line healthcare peer expect development ifrs appropriate presentation financial statement follow accounting policy revision major previously unrealise loss defer equity writtenoff result onetime expense billion swiss franc positive painful progress reposition roche groupwe exit noncore activity fully focus successful pharmaceutical diagnostic business roche finance provide solid platform value creation entrepreneurial development group erich hunziker chief financial officer financial review roche group reposition millions chf chugai alliance chugai complete group position forward strategic objective japan final purchase consideration acquisition accounting billion swiss franc overall consolidated net cash outflow billion swiss franc cash contribution chugai remain group consolidate balance sheet annual ongoing effect acquisition accounting include million swiss franc amortisation million swiss franc depreciation acquisition accounting result onetime net gain million swiss franc effectively sell nippon roche minority shareholder chugai fair value writeup million swiss franc inventory hold chugai date acquisition writtenoff inventory turn month october result additional expense million swiss franc million swiss franc half pharmaceutical division restructure fundamental restructuring programme announce largely com plete additional cost million swiss franc future cost anticipate restructure lead optimal cost structure focusse sale spend divestment vitamin fine chemical business sale vitamin fine chemical business complete subject regu latory approval expect close half base sign agreement dsm impairment net asset division total million swiss franc hasbeen record reduce profitability business initial announcement preliminary agreement dsm reduction market valuation business worldwide lead agree sale price vitamin fine chemical business significantly lower previous book value reduction drive impairment charge sale agreement liability respect vitamin case remain roche group additional expense record million swiss franc represent resolution major litigation currently outstanding customer estimate remain likely litigation cost worldwide genentech legal case follow court judgement group subsidiary genentech record provision million swiss franc main litigation concern relate allege breach agreement genentech city hope medical center genentech appeal thejudgement announce group halfyear result provision record financial statement financial reviewtreasury financing group take step restructure treasury financing operation thestrategic objective high risk take financial investment line group healthcare peer time group evaluate option restruc ture debt financing aim reduce debt level simplify funding structure well align funding level operate need development world market reduce fair value group equity portfolio result large unrealised loss defer equity consistent strategic objec tive roche decide proactively revise accounting policy availableforsale financial asset future investment market value original cost sustain sixmonth period consider impair loss automati cally record income statement defer equity onetime impact revision accounting policy recognise unrealise loss billion swiss franc december impairment charge effect amount reclassify fair value reserve equity retain earning income statement impact balance sheet value financial asset record atmarket value january impact net income chugai transaction net gain acquisition accounting inventory fair value adjustment writeoff pharmaceutical division restructuring vitamin fine chemical division discontinuing operation include tax impairment net asset vitamin case major legal case impairment financial asset income taxis minority interest total impact financial review operating result million chf sale doubledigit growth oncology transplantation diagnostic change change local chf currency pharmaceutical total prescription roche prescriptiona genentech prescription japan prescriptionc otc diagnostic sale adjust basis vitamin fine chemical reclassificationa total sale pharmaceutical division sale adjust include reclassification sale vitamin fine chemical division exclude nippon roche classify japan prescription segment consist chugai october nippon roche january september strong performance oncology transplantation franchise prescription business afurther doubledigit growth diagnostic sale consolidation chugai october increase adjust group sale local currency million swiss franc chugai contribute slightly percentage point group growth percentage point growth pharmaceutical total prescription business significant sale increase achieve spite adverse impact generic roaccutaneaccutane particular second half sale pharmaceutical account group core business diagnostic geographically north america contribute europe japan rest world total group sale adjust basis financial reviewoperate profit doubledigit increase margin improvement group pharmaceutical diagnostic change change local chf currency sale cost sale gross profit marketing distribution research development administration amortisation intangible asset impairment longterm asset operating income expense net operating profit adjust basis adjustment item page total operating profit operating profit increase local currency swiss franc billion swiss franc adjust basis exclude vitamin fine chemical business special item increase primarily drive sale growth improve cost structure result pharmaceutical division restructuring gain approximately million swiss franc continue product portfolio asset realignment pharmaceutical diagnostic increase operating profit margin respectively group operate profit margin sale increase percentage point previous year gross profit increase swiss franc billion swiss franc gross profit margin improve percentage point reflect particularly strong growth highmargin pharmaceutical diagnostic product effect continue produc tivity improvement marketing distribution increase swiss franc billion swiss franc underproportional sale growth cost increase pegasys fuzeon product launch partially offset focused spend growth area result restructure marketing distribution percentage sale fall percentage point research development increase swiss franc billion swiss franc support strong research development pipeline core business intensify inlicense arrangement research development cost percentage sale group level reach increase percentage point pharmaceutical account group research development expense increase administration increase swiss franc billion swiss franc mainly integration chugai corporate project financial review amortisation intangible asset increase decrease swiss franc bil lion swiss franc local currency amortisation charge increase mainly acquisition chugai october fall swiss franc mainly drive foreign exchange movement significant group intangible asset denominate dollars euro japanese yen roche amortisation charge currently sale continue significantly high industry average follow implementation ofrecent change company united states generally accept accounting principle usgaap long require amortise goodwill instead carry regular impairment review roche continue amortise goodwill include hold genentech require international financial reporting standard ifrs goodwill amortisation expense million swiss franc operating income expense net decrease swiss franc net expense million swiss franc million swiss franc reduction net expense mainly drive gain approximately million swiss franc continue product portfolio asset realignment particular gain disposal neupogen million swiss franc second half divisional resultsin million chf divisional ebitda operate sale operating profit party ebitda sale profit sale pharmaceutical total prescription roche prescription genentech prescription japan prescription otc diagnostic group total adjust basis adjustment item page group total pharmaceutical total prescription roche prescription genentech prescription japan prescription otc diagnostic group total adjust basis adjustment item page group total adjusted figure internal management roche group represent result group underlie ongoing operation exclude special item include continue business seepage description reconciliation financial reviewpharmaceutical operate profit ebitda margin improve operating profit increase billion swiss franc represent sale ebitda total billion swiss franc ebitda margin increase strong result drive prescription business otc result weaken compare previous year total prescription sale increase local currency primarily drive strong performance oncology franchise key product cellcept neorecormon partly offset impact generic roaccutaneaccutane consolidation chugai october contribute percentage point growth prescription business marketing distribution cost increase line sale increase cost launch new product pegasys fuzeon partially offset focused spend growth area result pharmaceutical division restructure research devel opment pipeline complement number inlicense deal increase cost substantially upfront milestone payment result include gain disposal neupogen million swiss franc acquisition chugai order improve comparability japan prescription business report separately consist nippon roche prescription business september chugai october consequently roche prescription business show report exclude business japan year profitability roche prescription business improve operate profit margin genentech prescription business achieve strong sale profit growth ebitda margin represent genentech strong contribution group operate cash generation operating profit genentech include million swiss franc amortisation mainly arise acquisition genentech roche japan prescription business grow result acquisition chugai operate profit margin decrease strength swiss franc relative japanese yen high launch costsfor new product recur acquisition accounting charge annualise basis acquisition accounting impact approximately million swiss franc otc sale fall local currency main factor weak sale aleve eco nomic difficulty latin america operating profit decrease million swiss franc primarily decline sale startup cost new production facility absence second half gain product disposal ongoing product portfolio streamline intensify marketing effort product rollout second half operate profit margin compare diagnostic strong result sale development significantly outperform market overall growth rate local currency sale growth high margin business area molecular diagnostic diabetes care particularly strong operating profit increase million swiss franc ebitda million swiss franc profitability improve operate profit margin percentage point ebitda margin percentage point increase operating cost particular research develop ment licensing activity offset strong sale growth result consist cost corporate headquarters cost increase compare mainly launch corporate initiative financial review financial income expense net millions chf impairment financial asset impairment charge million swiss franc major impact group result charge arise accumulate effect group equity portfolio fall world market year especially month group revise accounting policy mean significant fall automatically recognise expense accumulate deferral equity underlie net financial income net financial income adjust basis decrease million swiss franc exclude net financial expense million swiss franc attributable vitamin fine chemical business significant item gain million swiss franc disposal labcorp share gain equity derivative include million swiss franc respect lock labcorp gain derivative exclude labcorp adjust financial income net expense million swiss franc broadly expect net income equity investment exclude labcorp million swiss franc difficult market environment limited possibility realise gain interest income million swiss franc decrease relative prior year cause fall interest rate interest expense fall million swiss franc fall interest rate impact amortisation rate discount debt instrument fix breakdown net financial income give note financial statement income taxesin million chf major event uneven tax impact result tax expense million swiss franc pretax loss million swiss franc impact show table note significant impairment financial asset cause pretax lossof billion swiss franc little tax impact investment hold lowtax jurisdiction adjust basis effective tax rate increase mainly operating income make increasingly high proportion pretax income previously case increasingly positive impact genentech chugai pretax profit result increase tax rate consequently adjusted pretax income low tax expense high associate company minority interest millions chf report result cost genentech legal case attributable minority underlie expense minority interest continue increase overall contribution genentech net income increase comparative result income asso ciate company consist mainly income labcorp period prior june time account associate company remain associate company notably basilea pharmaceutica currently generate net expense financial reviewnet income millions chf report basis major event result net loss million swiss franc adjust basis net income low million swiss franc increase operating profit offset low financial income proportionately high tax charge cash flow net liquidity million chf cash flow statement cash generate business operation operate cash flow operating activity income taxis income taxis pay activity operating activity financing activity invest activity net effect currency translation cash increase decrease cash group operation continue strong grow operate cash generation billion swiss franc drive continued growth ebitda operate cash surplus largely absorb payment total billion swiss franc respect major legal case payment follow vitamin case fine million swiss franc vitamin case settlement payment direct indirect vitamin customer united states million swiss franc igen litigation payment million swiss franc collateral deposit account pende resolution litigation operate cash flow increase additional contribution million swiss franc pay group pension plan increase taxis pay reflect settle ment increase tax expense note include taxis pay labcorp gain significant financing cash flow payment dividend shareholder billion swiss franc repayment date billion yen samurai bond cash outflow billion swiss franc outflow include billion swiss franc cash pay genentech repurchase share party invest cash flow include impact chugai antisoma alliance bil lion swiss franc proceed sale labcorp share march july capital expenditure slightly increase major acquisition divestment fund themajor cash outflow describe take group marketable security portfolio account remainder inflow year demerger vitamin fine chemical division complete half division cash flow include figure financial review net liquidity december december cash marketable security financial longterm asset derivative financial instrument net equity instrument financial asset longterm debt shortterm debt total debt net liquidity net liquidity decrease billion swiss franc million swiss franc significant outflow follow vitamin case payment billion swiss franc dividend payment billion swiss franc fall fair value marketable security billion swiss franc large outflow partly offset cash generate operation ebitda total billion swiss franc group debt instrument lyon helveticus bullet bond total billion swiss franc classify repayable year sale labcorp share effect net liquidity simple term transfer frommarketable security cash similarly repayment samurai bond effect areduction shortterm debt cash billion swiss franc certain major item foreseeable include proceed demerger vitamin fine chemical division settlement remain vitamin case provision propose dividend payment repayment lyons helveticus bullet debt instru ment reduce cash affect net liquidity debt reduce balance sheet million chf change longterm asset current asset total asset equity minority interest noncurrent liability current liability total equity minority interest liabilitie financial reviewforeign currency translation effect fall value dollar relative swiss franc significant impact certain balance sheet heading particularly intangible asset longterm debt minority interest relatively high proportion dollar denominate item effect movement euro japanese yen relative theswiss franc significant impact chugai completion alliance chugai october significant impact balance sheet net acquire asset include fair value adjustment billion swiss franc billion swiss franc attributable minority disposal nippon roche increase minority interest million swiss franc provision litigation vitamin case relate payment total billion swiss franc reduce current liability partly offset billion swiss franc increase provision book second half remain provision respect vitamin case classify shortterm igen litigation relate payment million swiss franc collateral deposit account reduce current asset increase longterm asset provision genentech legal case million swiss franc include noncurrent lia bilitie longterm asset increase current asset decrease million swiss franc follow reclassification certain genentechs investment longterm note equity financing repayment samurai bond reduce current liability billion swiss franc lyons helveticus bullet bond book value bil lion swiss franc show current liability payment dividend reduce equity billion swiss franc net loss period decrease equity sale labcorp share mean unrealised gain hold equity takenout equity recognise income statement impairment financial asset overall impact total equity effect transfer fair value reserve retain earning income statement group obligation repurchase equity instrument connection sumo lyon reclassify equity longterm debt discount value billion swiss franc effect currency trans lation reduce net asset equity billion swiss franc movement property plant equipment intangible asset decrease billion swiss franc million swiss franc impairment charge vitamin fine chemical division depreciation amortisation fall dollar minor ity interest stable increase respect chugai largely offset decrease result ing share repurchase genentech fall dollar strong financial condition group remains solidly finance recent event significant impact equity include minority interest represent total asset compare end spite total asset finance longterm net liquidity reduce billion swiss franc financial review subsequent event february roche disetronic announce plan group acquire infusion system division disetronic disetronic world leader research development insulin pump treatment diabete propose acquisition subject approval competition authoritie disetronic shareholder total net cost acquisition expect approximately billion swiss franc foreign exchange rate exchange rate swiss franc december average december average december usd eur gbp jpy chfusd exchange rate financial reviewthe adjust basis concept adjust basis management view group ongoing operation present consistent comparable basis consolidated result roche group significantly influence special item change international financial reporting standard year improve thevisibility underlie business adjust result present adjust result internal management business represent result thegroup underlie ongoing operation principle compile adjust result apply consistent basis major concept follow adjust result include gain loss continue product portfolio asset realignment sale income newly acquire product impact sale income patent expiry withdrawal disposal exist product impairment longterm asset major restructuring cost normal ongoing restructuring gain loss sale marketable security adjust result exclude gain loss arise disposal fully consolidate subsidiary associate company discontinue operation sale spinoff business onetime cost major restructure fundamental reorganisation charge exceptional legal case transition effect change revision accounting policy specific item exclude adjusted result adjust result exclude gain disposal nippon roche nonrecurre charge relate chugai transaction result vitamin fine chemical division include impairment net asset additional charge relate vitamin case nonrecurre cost pharmaceutical division restructure additional charge respect major legal case impairment financial asset adjust result exclude result vitamin fine chemical division include impairment net asset additional charge relate vitamin case nonrecurre cost pharmaceutical division restructure financial review income statement millions chf figure report figure report financial statement adjust basis change change sale cost sale gross profit marketing distribution research development administration amortisation intangible asset impairment longterm asset chugai transaction pharmaceutical division restructuring vitamin fine chemical division impairment net asset vitamin case major legal case operate income expense net operating profit financial income expense net impairment financial asset profit taxis income taxis profit taxis income applicable minority interest share result associate company net income dilute earning share nonvoting equity security chf financial reviewreconciliation report figure adjust basisin million chf reference number indicate corresponding note consolidated financial statement sale operating year end december party ebitda profit net income report consolidated financial statement gain loss fully consolidate subsidiary associate company net gain disposal nippon roche reduction total consideration pay chugai impact fair value adjustement chugai inventory discontinue operation result vitamin fine chemical division reclassification intercompany sale vitamin fine chemical division sale party impairment net asset vitamin fine chemical division additional charge respect vitamin case major restructuring nonrecurre cost pharmaceutical division legal case additional charge respect genentech legal case transition effect change revision accounting policy impairment financial asset income taxis income applicable minority interest result adjust basis sale operating year end december party ebitda profit net income report consolidated financial statement discontinue operation result vitamin fine chemical division reclassification intercompany sale vitamin fine chemical division sale party additional charge respect vitamin case major restructuring nonrecurre cost pharmaceutical division income taxis result adjust basis financial review consolidated financial statement reference number indicate corresponding note consolidated financial statement consolidated income statement million chf year end december sale cost sale gross profit marketing distribution research development administration amortisation intangible asset impairment longterm asset chugai transaction pharmaceutical division restructuring vitamin fine chemical division impairment net asset vitamin case major legal case operate income expense net operating profit financial income expense net impairment financial asset profit taxis income taxis profit taxis income applicable minority interest share result associate company net income basic earning share nonvoting equity security chf dilute earning share nonvoting equity security chf number share share information restate share split take place seenote consolidated financial statementsconsolidate balance sheet millions chf december longterm asset property plant equipment intangible asset investment associate company financial longterm asset defer income tax asset longterm asset total longterm asset current asset inventory account receivable current income tax asset current asset marketable security cash cash equivalent total current asset total asset equity share capital nonvoting equity security genussscheine equity instrument retain earning fair value reserve total equity minority interest noncurrent liability longterm debt defer income tax liability liabilitie postemployment benefit provision noncurrent liability total noncurrent liability current liability shortterm debt current income tax liability provision account payable accrue current liability total current liability total equity minority interest liability pro memoria nonvoting equity securities nominal value note consolidated financial statement consolidate statement change equity million chf year end december share capital balance january december nonvoting equity security genussscheine balance january december equity instrument balance january movement year employee share option plan reclassification obligation repurchase equity instrument balance december retain earning balance january net income dividend pay balance december fair value reserve balance january increase decrease fair value income expense recognise income statement defer income taxis minority interest equity component new convertible debt currency translation gain loss balance december total equity december pro memoria nonvoting equity securities nominal value note consolidated financial statementsconsolidate cash flow statement million chf year end december cash flow operating activity cash generate operation increase decrease work capital cost pharmaceutical division restructuring pay cost vitamin case pay igen litigation payment collateral deposit account payment define benefit postemployment plan operate cash flow cash flow operating activity income taxis pay income taxis pay total cash flow operating activity cash flow financing activity proceed issue longterm debt repayment longterm debt transaction equity instrument increase decrease shortterm borrowing interest dividend pay genentech stock repurchase finance cash flow total cash flow financing activity cash provide operating financing activity cash flow invest activity purchase property plant equipment intangible asset disposal property plant equipment intangible asset acquisition subsidiary associate company product divestment subsidiary associate company product proceed sale labcorp share interest dividend receive sale purchase marketable security net invest cash flow total cash flow investing activity net effect currency translation cash increase decrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year consolidated financial statement note consolidated financial statement reference number indicate corresponding note consolidated financial statement summary significant accounting policy basis preparation consolidate financial statement consolidate financial statement roche group prepare accordance international financial reporting standard include standard interpretation issue international accounting standard board prepare historical cost convention disclose accounting policy certain item include derivative availableforsale investment show fair value approve forissue board director february preparation consolidated financial statement require management estimate assumption affect report amount revenue expense asset liability disclosure contingent liability date financial statement future estimate assumption base management good judgement dateof financial statement deviate actual circumstance original estimate assumption modify appropriate year circumstance change necessary comparative reclassify extend previously report result account presentational change consolidation policy financial statement consolidate financial statement roche holding ltd acompany register switzerland subsidiary group subsidiary company control directly indirectly roche holding ltd control define power govern financial operating policy enter prise obtain benefit activity control normally evidence roche holding ltd own directly indirectly vote right company share capital company acquire year consolidated date operating control transfer group subsidiary divest include date divestment company acquire resold consolidated classify asset hold sale carry fair value asset identify divestment follow year reclassify asset hold sale current asset asset normally consist mainly inventory property plant equipment longterm asset investment associate company account equity method com panie group exercise significant influence control isnormally evidence group own voting right company interest joint venture report linebyline proportionate consolidation method note consolidated financial statementsforeign currency translation group company use local currency measurement currency certain group company use currency dollar swiss franc euros measurement currency usefully represent result financial position com panie give local economic condition circumstance local transaction curren cie initially report exchange rate date transaction gain loss settlement transaction gain loss monetary asset liability denominate currency include income deferred equity qualifying cash flow hedge consolidation asset liability group company measurement currency swiss franc foreign entity translate swiss franc yearend rate exchange sale cost expense net income cash flow translate average rate exchange year translation difference change exchange rate begin end year difference net income translate average yearend exchange rate take directly equity divestment foreign entity identify cumulative currency translation difference relate foreign entity arerecognise income gain loss divestment revenue cost sale sale represent amount receive receivable good supply service render tocustomer deduct trade discount volume rebate exclude sale value add taxis cash discount record marketing distribution expense revenue fromthe sale product recognise transfer customer significant risk reward usually shipment royalty income recognise accrual basis accordance economic substance agreement revenue record earn theservice perform cost sale include correspond direct production cost relate production overhead good manufacture service render research development research cost charge income incur exception building major item equipment capitalise depreciate development cost capitalise intangible asset probable future economic benefit flow thegroup intangible asset amortise straightline basis period expect benefit review impairment balance sheet date develop ment cost charge income incur criterion recognition anasset meet note consolidated financial statement inlicense milestone upfront receipt payment certain group company notably genentech receive thirdpartie upfront milestone similar nonrefundable payment relate sale licensing product technology revenue associate performance milestone recognise base achievement milestone define respective agreement revenue nonrefundable upfront payment licence fee initially report deferred income recognise income asearne period development collaboration manufacturing obligation payment group company party associate company item charge income research development cost probable future economic benefit flow group normally evidence regulatory approval case capitalise development cost amortise describe practice mean inlicense milestone payment pharmaceutical product expense incur case gain regulatory approval receipt payment consolidate subsidiary genentech roche group subsidiary eliminate consolidation employee benefit wage salary social security contribution pay annual leave sick leave bonus nonmonetary benefit accrue year associate service render employee group group provide longterm employee benefit cost accrue match rendering service employee concerned group operate number define benefit define contribution plan world cost year define benefit plan determine project unit credit method reflect service render employee date valuation incorporate actuarial assumption primarily discount rate determine present value benefit project rate remuneration growth longterm expect rate return planasset discount rate base market yield highquality corporate bond country concern difference assumption actual experience effect change actuarial assumption allocate estimate average remain work live employee difference exceed define corridor past service cost allocate average period benefit vested pension asset liability different define benefit scheme offset group legally enforceable right use surplus plan settle obligation plan pension asset recognise extent group able derive future economic benefit way refund plan reduction future contribution group contribution define contribution plan charge income statement year relate taxation income taxis include taxis base taxable profit group include withhold taxis payable distribution retain earning group taxis base onincome property capital taxis include operating expense financial expense accord nature provision income taxis mainly withhold taxis arise remittance retain earning principally relate subsidiary current inten tion remit earning note consolidate financial statementsdeferred income tax provide liability method temporary difference tax basis asset liability carry amount financial statement defer income tax asset relate carryforward unused tax loss recognise extent probable future taxable profit available unused tax loss utilise current defer income tax asset liability offset income taxis leviedby taxation authority legally enforceable right offset deferred income taxis determine base currently enact tax rate applicable tax jurisdiction group operate property plant equipment property plant equipment initially record cost purchase construction depreciate straightline basis land depreciate estimate useful life major class depreciable asset follow building land improvement year machinery equipment year office equipment year motor vehicle year investment grant similar assistance project initially record deferred income inoth noncurrent liability subsequently recognise income useful life relate asset repair maintenance cost recognise expense incur borrowing cost capitalise asset acquire finance lease depreciate estimate useful life payment operating lease charge income straightline basis period lease intangible asset business combination goodwill record intangible asset surplus cost acquisition fair value identifiable net asset acquire goodwill fair value adjustment treat asset liability acquire company record local currency company patent licence trademark intangible asset initially record fair value asset acquire business combination fair value allocate acquisition accounting acquire business combination initial fair value cost intangible asset amortise useful life straightline basis estimate useful life major class intangible asset follow goodwill year patent licence trademark low legal duration intangible asset economic useful life maximum year note consolidated financial statement impairment longterm asset recoverable asset high net selling price value inuse carrying carry reduce recoverable value reduction report income statement impairment loss value use calculate estimate cash flow generally fiveyear period extrapolate projection subsequent year discount appropriate longterm pretax interest rate impairment arise useful life asset question review ifnecessary future depreciationamortisation charge accelerate inventory inventory state low cost net realisable value cost determine firstout method cash cash equivalent cash cash equivalent comprise cash hand time current balance bank similar institution readily convertible know amount cash subject insignificant risk change value definition cash flow statement equity instrument group holding equity instrument record deduction equity original cost acquisition consideration receive subsequent resale equity instru ment movement report change equity instrument acquire primarily meet obligation arise respect certain group debt instrument december group revise accounting policy classification obliga tion repurchase equity instrument show liability measure present value final obligation discount appropriate longterm pretax interest rate discount future amortise duration obligation recognise interest expense income statement debt instrument debt instrument initially report cost proceed receive net transaction cost subsequently report amortise cost effective interest method extent debt instrument hedge qualify fair value hedge hedge item record fair value discount net proceed receive principal value redemption amortise duration debt instrument recognise interest expense income statement issue convertible debt instrument cost liability portion initially calculate market interest rate equivalent nonconvertible instrument remainder thenet proceed allocate equity conversion option report equity defer income tax liability equity conversion option share consolidated subsidiary portion net proceed attributable option record minority interest liability element subsequently report amortise cost amortisation debt discount release defer tax liability recognise income statement duration debt instrument value equity conversion option change future period limited conversion prefer stock substance financial liability equity instrument classified longterm debt balance sheet relate dividend payment treat interest expense note consolidated financial statementsprovision provision recognise legal constructive obligation incur probably lead outflow resource reasonably estimate provision record estimate ultimate liability expect arise take account foreign currency effect time value money contingent liability disclose existence obligation confirm future event obligation measure reasonable reliability fair value fair value financial asset liability instrument exchange knowledgeable willing party arm length transaction determine reference quote market price adjust estimate transaction cost incur actual transaction use establish estimation technique option pricing model estimate discount value cash flow fair value balance sheet date approximately line report carry value specifically mention note consolidated financial statement financial asset financial asset principally investment include marketable security classify heldfortrade availableforsale heldtomaturity originate group heldfor trade financial asset acquire principally generate profit shortterm fluctuation inprice heldtomaturity financial asset security fix maturity group intent ability hold maturity financial asset originate group loan andother longterm financial asset create group acquire issuer primary market financial asset consider availableforsale financial asset initially record cost include transaction cost purchase sale recognise settlement date heldfortrade financial asset subsequently carry fair value change fair value record financial income expense period arise heldtomaturity financial asset subsequently carry amor tise cost effective interest rate method availableforsale financial asset subse quently carry fair value unrealise change fair value record equity availableforsale financial asset sell impair dispose cumulative gain loss previously recognise equity include financial income expense current period financial asset originate group subsequently carry amortise cost financial asset assess possible impairment balance sheet date impairment charge record objective evidence impairment issuer bankruptcy default significant financial difficulty december group revise accounting policy impairment financial asset addition impairment trigger availableforsale financial asset market value original cost sustain sixmonth period consider impaired fall market price original cost orfor sustained sixmonth period consider objective evidence impairment movement fair value record equity isobjective evidence impairment asset sell dispose note consolidated financial statement derivative derivative financial instrument initially record cost include transaction cost derivative subsequently carry fair value apart derivative designate qualify cash flow hedge instrument change fair value arerecorde financial income expense period arise hedging purpose hedge accounting hedging relationship type fair value hedge hedge particular risk change fair value recognise asset liability cash flow hedge hedge particular risk change time offuture cash flow hedge net investment foreign entity hedge particular risk change carry value net asset foreign entity qualify hedge accounting hedging relationship meet strict condition ondocumentation probability occurrence hedge effectiveness reliability measurement condition meet relationship qualify hedge accounting inthis case hedge instrument hedge item report independently hedge relationship particular derivative report fair value change fair value include financial income expense qualify fair value hedge hedge instrument record fair value hedge item record previous carrying value adjust change fair value attributable hedged risk change fair value report financial income expense qualify cash flow hedge hedge instrument record fair value portion change fair value effective hedge include equity remain inef fective portion report financial income expense hedge relationship hedge firm commitment highly probable forecast transaction cumulative change fair value hedge instrument record equity include initial car rye value asset liability time recognise qualify cash flow hedge cumulative change fair value hedge instrument record equity include financial income expense time forecast transaction affect net income qualifying hedge net investment foreign entity hedge instrument record fair value portion change fair value effective hedge include equity remain ineffective portion record financial income expense hedge instrument derivative equity case entity dispose cumu lative change fair value hedge instrument record equity include financial income expense time disposal international financial reporting standard revise new standard interpretation effective january significant effect group financial statement note consolidated financial statementschange effective january revise new standard interpretation effective january theprincipal item affect group standard financial instrument recognition measurement implement change result increase equity million swiss franc effective january include comparative opening balance consolidated financial statement change fully describe consolidated financial statement future development international financial reporting standard international financial reporting standard continue develop come year theinternational accounting standard board publish exposure draft atthe time ofpublication financial statement new standard adopt thatwould need apply financial risk management financial risk management group govern policy guideline approve senior management policy guideline cover foreign exchange risk interest rate risk market risk credit risk liquidity risk group policy guideline cover area cash management investment excess fund raise short longterm debt group company report detail financial instrument outstanding financial liquidity group treasury monthly basis new post financial risk manager create oversee compliance group financial risk management policy guideline policy group accordance risk management guideline continue monitor risk deem appropriate certain risk significantly alter use financial instrument derivative group management believe order create optimum value group desirable eliminate mitigate possible market fluctuation foreign exchange risk group operate world expose movement foreign currency affect net income financial position express swiss franc group continue monitor currency exposure appropriate enter transaction aim preserve value asset commitment anticipate transaction group use forward contract foreign currency option optimise certain anticipate foreign exchange revenue cash flow financing transaction transaction exposure arises local currency pay receive trans action denominate foreign currency vary change exchange rate group company income primarily local currency significant expendi ture especially purchase good resale interest repayment loan foreign currency similarly transaction exposure arise net balance monetary asset hold foreign currency group company manage exposure local level necessary mean financial instrument option forward contract addition group treasury monitor total worldwide exposure help comprehensive datum receive monthly basis note consolidated financial statement translation exposure arise consolidation foreign currency denominate finan cial statement group foreign subsidiary effect group consolidated equity show currency translation movement group hedge significant net investment foreign currency take foreign currency loan issue foreign currency denominate debt instrument major translation exposure monitor regular basis significant group cash outflow research development production admin istration denominate swiss franc small proportion group cash inflow swiss franc denominate result increase value swiss franc rela tive currency adverse impact consolidate net income similarly relative fall value swiss franc favourable effect result publish swiss franc interest rate risk interest rate risk arise movement interest rate adverse effect thegroup net income financial position change interest rate cause variation interest income expense interestbeare asset liability addition affect market value certain financial asset liability instrument describe follow section market risk interest rate group major debt instrument fix asdescribed note reduce group exposure change interest rate group company manage shortterm interest rate risk local level necessary financial instrument interest rate forward contract swap option market risk change market value certain financial asset liability instrument affect net income financial position group longterm investment hold strategic pur pose marketable security hold fund management purpose risk loss value reduce review prior invest concentration investment continuous monitoring performance investment change risk configuration investment equity fix income instrument enter basis approve guideline regard liquidity credit rating credit risk credit risk arise possibility counterparty transaction unable unwilling meet obligation cause financial loss group trade receivables subject policy active risk management focusse assessment country risk credit availability ongoing credit evaluation account monitor procedure signifi concentration trade receivables counterparty credit risk group large number customer wide geographical spread country risk limit exposure continuously monitor exposure financial asset credit risk control set ting policy limit credit exposure highquality counterpartie ongoing review credit rating limit individual aggregate credit exposure accordingly note consolidated financial statementsliquidity risk group company need sufficient availability cash meet obligation individual company responsible cash management include shortterm investment cash surplus raise loan cover cash deficit subject guidance group certain case approval group level group maintain sufficient reserve cash readily realisable marketable security meet liquidity requirement times addition strong international creditworthiness group allow efficient use international capital market financing purpose group organisation overview subsidiary associate company include page change group organisation chugai chugai alliance discuss note vitamin fine chemical division demerger vitamin fine chemical division discuss note antisoma investment antisoma treat associate company discuss note change group organisation amira november group acquire share capital amira medical inc amira amira company active diabete monitor base united states netconsideration pay million swiss franc allocate follow net asset acquire millions chf goodwill intangible asset defer income taxis provision net asset liability total note consolidated financial statement segment information millions chf divisional information roche genentech japan prescription prescription prescription otc segment revenue segment revenuedivisional sale interdivisional sale divisional sale party segment resultsoperate profit segment asset liabilitie divisional asset segment asset segment asset nonsegment asset total asset divisional liability segment liability segment liability nonsegment liability total liability segment information capital expenditure depreciation amortisation impairment longterm asset research development cost major legal case vitamin case share result associate company investment associate company number employee group division pharmaceutical diagnostic vitamin fine chemical disclosure pharmaceutical division include reportable segment roche prescription genentech prescription japan prescription otc japan prescription business segment include result newly merge chugai company include nippon roche business october include result nippon roche period september nippon roche result reclassify segment roche prescription segment japan prescription note result chugais otc business include japan prescription business segment vitamin fine chemical division process demerge consider noncore business note segment consist cost corporate headquarters cost reasonably attribute report segment note consolidated financial statementstotal core vitamine pharmaceutical diagnostic business fine chemical group transfer price interdivisional sale set arm length basis divisional asset consist primarily property plant equipment goodwill intangible asset receivables inventory divisional liabili tie consist trade account payable segment asset liability consist asset liability reasonably attribute report business segment include pension asset liability provision nonsegment asset liability mainly include current defer income tax balance financial asset liability principally cash marketable security investment associate company investment debt capital expenditure comprise addition intangible asset include goodwill addition property plant equipment include arise acquisition note consolidated financial statement geographical information sale party destination segment asset capital expenditure switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania segment total nonsegment asset consolidate total segment asset include property plant equipment goodwill intangible asset receivables inventory trade account payable asset reasonably attribute report geographical segment nonsegment asset mainly include current defer income tax balance financial asset principally cash marketable security investment associated company investment capital expenditure comprise addition intangible asset include goodwill addition property plant equipment include arise acquisition genentech effective september group acquire majority interest approximately genentech inc biotechnology company united states june group exer cise option acquire remain share genentech june point genentech own subsidiary group july october march group complete public offering genentech common stock result note consolidated financial statementsof group majority interest genentech issue additional share common stock connection equity compensation plan issue additional share purpose affiliation agreement group genentech provide thing genentech establish stock repurchase programme maintain group percentage ownership interest genentech december group interest genentech common stock genentech publicly trade list new york stock exchange symbol dna genentech incorporate delaware principal executive office south san francisco california market capitalisation december billion dollar billion swiss franc genentech prepare financial statement conformity accounting principle generally accept united states gaap file quarterly basis securities exchange commission certain consolidation entry difference requirement international financial reporting standard ifrs gaap difference genentech standalone result gaap basis result genentech consolidate roche group accordance ifrs reconcile table usd chf usd chf million million million million net income gaap basis add nonoperate item gaap basis change gaap accounting policy income taxis net financial income add deduct ifrs gaap difference consolidation entry amortisation goodwill capitalise iprd amortisation goodwill goodwill difference consolidation entry add gaap litigation charge deduct litigation charge ifrs basis segment resultoperate profit ifrs basis add deduct nonoperate item ifrs basis financial income expense net income taxis net income ifrs basis minority interest percentage average year income applicable minority interest ifrs basis operate profit ifrs basis exclude litigation charge net income ifrs basis exclude litigation charge impairment financial asset income applicable minority interest ifrs basis exclude litigation charge impairment financial asset note consolidated financial statement difference ifrs gaap follow acquisition group interest genentech june analy sis carry acquisition accounting identify total million dollar attributable inprocess research development iprd genentech gaap financial statement item record adjustment equity onetime expense ifrs item classify separate asset date acquisition form goodwill year subsequent goodwill amortisation expense respect iprd group result ifrs genentech adopt accounting standard fas fas effective january goodwill long amortise subject impairment test annually ifrs goodwill continues amortise subject testing impairment genentech stock repurchase stock option october genentechs board director authorise stock repurchase programme torepurchase million dollar genentech common stock august genentechs board authorise extension repurchase additional million com mon stock genentech repurchase million dollar million swiss franc common stock common stock worth million dollar million swiss franc repurchase include million dollar million swiss franc thatwas repurchase prior october genentech stock option plan adopt amend plan allow thegrante stock option stock award stock appreciation right employee director consultant genentech movement number option hold genentech employee follow outstanding january issue exercised cancellation outstanding end period exercisable option issue year average exercise price usd optionsexercised year exercise average price usd cash inflow genentech stock option employee stock plan million dol lar million swiss franc million dollar million swiss franc blackschole option valuation model fair value option issue million dollar million swiss franc million dollar million swiss franc net accounting effect stock repurchase stock option record minority interest note matter discuss note group record provision million dollar million swiss franc respect certain litigation matter include litigation involve city hope january group issue lyon zero coupon dollar note exchange able genentech share note convert group percentage owner ship genentech decrease approximately note note consolidated financial statement chugai december roche chugai announce enter alliance create lead researchdriven japanese pharmaceutical company formed merger chugai exclude genprobe roche japanese pharmaceuticals subsidiary nippon roche term alliance chugai nippon roche inde pendently value roche agree additional cash contribution order bring roche participation agree combine value alliance approve share holder chugai annual general meeting june newly merge company know chugai fully consolidated subsidiary group roche majority shareholder ownership minority interest chugai domicile tokyo list tokyo stock exchange market capitalisation december billion japanese yen billion swiss franc transaction process lateseptember roche acquire public tender offer approximately mil lion shares chugais outstanding share price jpy share total cash outflow group result tender offer billion japanese yen million swiss franc immediately tender offer roche subscribe issue chugai million new share price jpy share result cash contribution tochugai billion japanese yen million swiss franc september closing tender offer roche chugai complete spinoff shareholding ingenprobe californiabase diagnostic subsidiary register shareholder july october chugai merge nippon roche prior merger nippon roche issue convertible bond roche group roche obligation succeed chugai october roche acquire additional share chugai conversion bond pro portion share issue chugai conversion convertible bond previously issue chugai party chugai roches ownership reach result cash contribution billion japanese yen million swiss franc ongoing basis roche convert remain roche chugai share correspond conversion remain chugai roche maintain ownership chugai purchase consideration closing transaction october transaction account purchase method accounting consideration pay roche chugai consist firstly public tender offer secondly subscription new chugai share con version roche relate minority shareholder thirdly net asset nippon roche attributable minority shareholder nippon roche public company net asset nippon roche value reference fair value chugai share acquire exchange allocation show table jpy billion chf million public tender offer subscription billion jpy convertible bond billion jpy imply value nippon roche transaction cost purchase consideration chugai note consolidated financial statement acquisition accounting market value chugai share acquire billion japanese yen million swiss franc correspond market capitalisation chugai prior transaction purchase consideration billion japanese yen million swiss franc represent surplus billion japanese yen million swiss franc market value chugai share acquire surplus writtenoff record net asset chugai exceed market capitalisation result transaction gain billion japanese yen million swiss franc arise disposal nippon roche accordingly net income billion yen million swiss franc wasrecognise theincome statement amount acquire net asset chugai show table allocate good include billion japanese yen million swiss franc attributable inprocess research development international financial reporting standard item classify separate asset date acquisition form goodwill net asset acquire jpy billions chf millionsa property plant equipment goodwill intangible asset inventory defer income taxis liabilitie postemployment benefit provision net asset liability minority interest total translate september exchange rate jpy chf ongoing impact purchase accounting october chugais result include group consolidated financial state ment japan prescription show separate business segment segment information japan prescription business segment include result newly merge chugai company include nippon roche business october include result nippon roche period september comparability nippon roche result reclassify segment roche prescription tothe segment japan prescription result chugais otc business include japan prescription business segment segment information give note fair value adjustment arise acquisition accounting follow impact group financial statement quarter onwards jpy chf jpy chf jpy chf billion million billion millionsa billion millionsa writeoff fair value adjustment inventory depreciation property plant equipment amortisation acquire intangible asset amortisation goodwill impact operating profit defer income taxis impact net income translate december exchange rate jpy chf note consolidated financial statementsthe fair value adjustment inventory fully writtenoff line inventory turnover end quarter goodwill acquire intangible asset amortise straightline basis year year respectively pharmaceutical division restructure millions chf group announce reshape future growth initiative restructur ing pharmaceutical division objective improve longterm profitability division increase sale reduce division cost structure activity year show table significant additional cost expect restructuring expense impairment property plant equipment employee cost closure cost curtailment gain postemployment plan total restructuring expense restructure provision january additional provision create unused amount reverse amount utilise currency translation effect december vitamin fine chemical division millions chf early group announce plan demerge vitamin fine chemical division september group announce reach agreement subject execution final definitive purchase agreement necessary regulatory approval sell global vitamin fine chemical business dutch company dsm final purchase agreement sign february sale expect close half expect transaction price billion euro consist billion euro cash million share dsm value approximately million euro december exchange rate billion euro equivalent billion swiss franc vitamin fine chemical division treat discontinuing operation sale close continue include consolidated figure sale result asset liability net cash flow division roche group show discontinue operation follow table note consolidated financial statement continue operation discontinuing operation group statement income sale party expense impairment net asset operating profit financial income expense net impairment financial asset profit taxis income taxis profit taxis minority interest share result associate company net income balance sheet december property plant equipment intangible asset longterm asset current asset total asset longterm debt noncurrent liability current liability total liability net asset statement cash flow operating activity financing activity invest activity net effect currency translation cash increase decrease cash impairment net asset base final agreement group management estimate current carrying value net asset vitamin fine chemical business excess expect net proceed sale accordingly impairment million swiss franc record asset vitamin fine chemical division addition tax expense million swiss franc record base preliminary estimate tax liability arise disposal sale close half final gain loss thedisposal ofthe net asset vitamin fine chemical business include tax effect maybe different amount currently record note consolidate financial statementsvitamin case follow settlement agreement department justice pricing practice vitamin market overall settlement agreement class action suitbrought buyer bulk vitamin group record provision respect vitamin case provision group well estimate time total liability arise take account currency movement time value money provision legal fee record separately december base development litigation recent settlement negotiation group record additional provision million swiss franc december group reassess adequacy remain provision vitamin case base development litigation recent settlement negotiation mainly unite states direct customer previously opt class action settlement group record additional provision million swiss franc total payment year million swiss franc million swiss franc payment include fine impose european union total million euro million swiss franc settlement direct indirect customer united states total million dollar million swiss franc group seek resolve remain outstanding issue time final amount involve uncertain provision record base current litigation recent settlement agreement litigation negotiation progress possible ultimate liability different provision currently record january district columbia circuit court appeal rule nonus plaintiff bring claim court antitrust law allege damage suffer transaction outside united states connection vitamin case defendant include roche appeal decision provision record respect ofthis litigation eventual outcome uncertain stage demerger process liability respect vitamin case remain theroche group roche dsm sign indemnity cooperation agreement roche provide dsm certain indemnity guarantee connection vitamin case major legal case development year major legal case discuss include impact group result possible future development contingent liability total expense year million swiss franc respect genentech legal case igen litigation february united states district court maryland enter judgement civil litigation roche diagnostic gmbh germany rdg igen international inc igen claim relate licensing igen electrochemiluminescence ecl rdg court conclude breach licence agreement material igen right terminate licence agreement award igen million dollar compensatory damage million dollar punitive damage rdg appeal judge ment final resolution expect second half exist order court bar licence termination appeal proceeding complete whileany appeal progress rdg continue provide customer product andservice continue plan innovation base ecl technology note consolidated financial statement rdg previously boehringer mannheim litigation matter acquire boehringer mannheim rdg assess igen litigation adequacy provision record boehringer mannheim rdg reassess adequacy provision conclude base currently available information appropriate record additional provision point total provision liability rdg expect pay adjusted foreign currency translation effect time value money litigation process possible final obligation different total provision disclose prejudice rdg position current litigation provision significantly amount award court march roche diagnostic gmbh rdg pay million dollar million swiss franc collateral deposit account respect igen litigation report restrict cash financial longterm asset note additional provision record year genentech legal case group record provision million dollar million swiss franc respect certain litigation matter include litigation involve city hope june genentech announce los angeles county superior court jury vote award city hope medical center approximately million dollar compensatory dam age base find breach agreement genentech city hope june jury vote award city hope million dollar punitive damage case september genentech file notice appeal jury verdict damage awards california court appeal appeal process year depend scope review provision record award appeal process interest accrue total damage simple annual rate follow judgment interest million dollar million swiss franc record time cost provision interest expense note october genentech enter arrangement party insurance company post surety bond million dollar connection judgement arrangement genentech pledge million dollar cash andinvestment secure bond amount equivalent million swiss franc report restrict cash financial longterm asset note addition genentech party patent infringement suit file chiron corporation june district court eastern district california sacramento respect herceptin june court issue decision summary judgement motion file jury trial suit begin august follow phase trial base finding jury court enter judgement favour genentech november chiron file notice appeal court appeal federal circuit december genentech file notice crossappeal court august united states patent trademark office declare interference chiron patent involve lawsuit patent application exclusively license togenentech university pennsylvania relate antiher antibody declare interference patent office determine substantial question inventor chiron patent invent technology involve entitle patent connection second patent infringement lawsuit file march genentech chiron discovery case currently stay note consolidated financial statementsin connection patent infringement lawsuit file genentech glaxosmithkline glaxo september september genentech glaxo agree settlement pursuant genentech glaxo dismiss prejudice claim andor counter claim lawsuit previous patent infringement lawsuit file genentech glaxo involve patent settlement resolve end patent infringement claim glaxo genentech genentech party litigation describe genentech annual report quarterly sec filing matter far advanced matter refer employee benefit million chf wage salary social security cost postemployment benefit define benefit plan postemployment benefit define contribution plan employee benefit total employee remuneration charge employee benefit include relevant expenditure line function number employee yearend employee benefit consist mainly life insurance scheme certain insurance scheme provide medical dental cover postemployment benefit employee cover retirement benefit plan sponsor group company nature plan vary accord legal regulation fiscal requirement economic con dition country employee employ postemployment benefit consist postretirement healthcare life insurance scheme principally united states plan usually fund payment group employee trust inde pendent group finances plan unfunded liability obligation record group balance sheet amount recognise arrive operate profit postemployment define benefit plan follow current service cost interest cost expect return plan asset net actuarial gain loss recognise past service cost gain loss curtailment total include employee remuneration actual return plan asset negative return million swiss franc negative return million swiss franc september group pay additional contribution million dollar mil lion swiss francs postemployment define benefit plan subsidiary fall market value plan asset payment include contri bution pay table account recognise surplus fund pension plan note group consolidated financial statement beinclude actuarial calculation group pension expense balance note consolidated financial statement movement net asset liability recognise balance sheet postemployment define benefit plan follow begin year chugai total expense include employee remuneration contribution pay benefit pay unfunded plan reclassification prepay employee benefit currency translation effect end year amount recognise balance sheet postemployment define benefit plan follow fund plan actuarial present value fund obligation past present employee plan asset hold trust fair value plan asset excess deficit actuarial present value fund obligation unrecognise actuarial gain loss unrecognise past service cost net recognise asset liability fund obligation past present employee unfunded plan recognise liability actuarial present value unfunded obligation total recognise asset liability fund unfunded obligation past present employee report surplus recognise longterm asset deficit recognise liability postemployment benefit total net asset liability recognise amount include nonpension postemployment benefit scheme principally medical plan follow actuarial present value obligation past present employee plan asset hold trust fair value plan asset excess actuarial present value fund obligation unrecognised actuarial gain loss net recognise asset liability amount recognise balance sheet postemployment define benefit plan pre dominantly noncurrent report longterm asset noncurrent liability include fair value asset fund plan group nonvoting equity security fair value million swiss franc million swiss franc note consolidated financial statementsthe group operate define benefit scheme country actuarial assumption vary base local economic social condition range assumption theactuarial valuation significant define benefit plan country withstable currency interest rate follow discount rate project rate remuneration growth expect rate return plan asset healthcare cost trend rate stock appreciation right employee certain subsidiary group receive stock appreciation right sar compensation sar exercise vest period tothree year cash payment base market price group american depositary share adss point exercise exceed strike price grant priceat issuance group accrue expect cash outflow outstanding sar december accrual require equity compensation benefit group launch equity compensation plan describe thegenentech stock option plan discuss note roche option plan group offer nonvoting equity security option certain director management exercise price market price nonvoting equity security date issue option nontradable sevenyear duration vest phase basis year group cover obligation purchase nonvoting equity secu ritie derivative thereon cost instrument report equity instrument equity balance sheet option exercise cash receive credit equity instrument impact income statement employer social insurance cost administrative cost plan previous option compensation plan group purchase option directly party financial institution grant certain employee close exist option grant old plan continue option grant movement number option hold employee follow outstanding january issue exercised cancellation outstanding december detail option grant period follow issue date february expiry date february exercise price chf proceed option exercise million chf blackschole option valuation model fair value option issue million swiss franc note consolidated financial statement roche performance share plan group offer future nonvoting equity security grant certain director key senior management nonvoting equity security grant depend individual salary level achievement performance target link total shareholder return relative group peer threeyear period date grant target meet grant grant vest year cost plan accrue vest period grant base final cash outflow estimate balance sheet date year cost plan million swiss franc report relevant operating expense category group cover obligation purchase nonvoting equity security derivative thereon cost purchasing instrument report equity instrument equity balance sheet roche connect programme enable employee worldwide united states certain country regular deduction salary purchase nonvoting equity security administer independent party group make contribution programme allow employee purchase nonvoting equity security discount usually administrator purchase necessary non vote equity security directly market nonvoting equity security hold december programme operational october year cost plan million swiss franc report relevant operating expense category operate income expense net millions chf royalty income gain disposal neupogen operating income total operating income royalty expense operating expense total operating expense total operating income expense net october group complete sale amgen asset business relate toneupogen european union switzerland norway cash receive million swiss franc note consolidated financial statement financial income expense net millions chf gain sale equity security loss sale equity security gain labcorp transaction dividend income gain loss equity derivative net writedown impairment equity security net income equity security interest income gain sale debt security loss sale debt security writedown impairment longterm loan net interest income income debt security interest expense amortisation discount debt instrument gain loss interest rate derivative net time cost provision net interest expense foreign exchange gain loss net gain loss foreign currency derivative net net foreign exchange gain loss net financial income expense net total financial income expense net june group sell share labcorp result pretax gain incidental cost million swiss franc record financial income expense net net pretax cash inflow million swiss franc date sale group remain investment labcorp account availableforsale marketable security march july group sell remain share labcorp transaction result pretax gain incidental cost million swiss franc amount record financial income expense net net pretax cash inflow million swiss franc addition group realise gain million swiss franc equity derivative enter connection disposal labcorp share december group remain ownership interest labcorp outstanding derivative position labcorp equities impairment financial asset december group revise accounting policy impairment financial asset addition exist impairment trigger describe note availablefor sale financial asset market value original cost sustain month period consider impaired fall market price original cost sustained sixmonth period consider objective evidence impairment movement fair value record equity objective evidence impairment asset sell dispose note consolidated financial statement result revision accounting policy group record impairment charge million swiss franc effective december income taxis million chf income tax expense amount charge income statement follow current income taxis defer income taxis total charge income taxis group operate world subject income taxis different tax juris diction group calculate average expect tax rate weight average tax rate tax jurisdiction group operate rate increase operating income make considerably high proportion pretax income case previous year lead increase group effective tax rate operating income typically occur jurisdiction high tax rate compare financial income group average expect tax rate increase significance genentech chugai account increase rate defer tax asset record local statutory loss incur argentina clear utilise future local taxable income group effective tax rate reconcile group average expect tax rate follow group average expect tax rate tax effect argentina amortisation goodwill gain sale labcorp share nontaxable incomenondeductible expense difference core business effective tax rate tax effect pharmaceutical division restructure major legal case discontinue operation vitamin fine chemical division vitamin case chugai transaction disposal nippon roche chugai transaction writeoff fair value adjustment inventory vitamin fine chemical division impairment net asset impairment financial asset group effective tax rate impairment net asset vitamin fine chemical division impairment offinancial asset significant impact effective tax rate alarge impact profit tax whilst relatively minor impact tax charge note consolidated financial statementsincome tax asset liability amount recognise balance sheet income taxis follow current income taxis current income tax asset current income tax liability net current income tax asset liability balance sheet defer income taxis defer income tax asset defer income tax liability net defer income tax asset liability balance sheet increase current income tax asset relate payment vitamin case swiss withholding taxis subsequently reimburse deferred income tax asset recognise tax loss carry forwards extent realisation relate tax benefit probable group unrecognised tax loss million swiss franc defer income tax liability establish withholding tax taxis payable unremitted earning certain foreign subsidiary amount currently regard permanently reinveste unremitted earning total billion swiss franc december billion swiss franc defer income tax asset liability defer income tax charge credit attributable follow item property plant equipment restructure temporary intangible asset provision difference total net defer income tax asset liability begin year charge credit income statement charge credit equity chugai currency translation effect net defer income tax asset liability end year net defer income tax asset liability begin year issue debt instrument charge credit income statement charge credit equity change group organisation currency translation effect net defer income tax asset liability end year note consolidated financial statement property plant equipment million chf building land machinery improve construction land ment equipment progress total total net book value begin year chugai change group organisation genentech synthetic lease addition disposal transfer depreciation charge pharmaceutical division restructuring impairment charge vitamin fine chemical division impairment net asset impairment charge currency translation effect end year december cost accumulate depreciation net book value group subsidiary genentech synthetic lease certain facility california groups accounting policy consolidated discuss financial statement record effective january date property plant equipment increase million swiss franc similar increase longterm debt seenote exclude genentech synthetic lease december capitalise cost machinery equipment finance lease amount million swiss franc million swiss franc net book value asset amount million swiss franc million swiss franc operating lease commitment december future minimum annual payment noncancellable operating lease include genentech synthetic lease follow year year total minimum annual payment total rental expense operating lease include genentech synthetic lease million swiss franc million swiss franc group capital commitment purchase construction property plant equipment total billion swiss franc billion swiss franc note consolidated financial statement intangible assetsin million chf patent licence trademark goodwill total total net book value begin year chugai change group organisation addition disposal amortisation charge vitamin fine chemical division impairment net asset impairment charge currency translation effect end year december cost accumulate amortisation end year investment associate company joint venture millions chf associate company group investment associate company list account equity method share net income balance sheet value laboratory corporation america holdings usa basilea pharmaceutica switzerland investment account equity method total investment account equity method laboratory corporation america holdings group transaction labcorp share discuss note december group remain ownership interest labcorp basilea pharmaceutica group own noncontrolle interest basilea pharma ceutica ltd basilea basilea swiss biotechnology company antibacterial antifungal dermatology field basilea private company domicile basel share capital million swiss franc december antisoma december group acquire interest antisoma plc antisoma million swiss francs antisoma british biopharmaceutical company develop product treatment cancer public company domicile london share trade london stock exchange nasdaq europe market capitalisation asat december million pound million swiss franc follow acqui sition group material transaction antisoma access development milestone payment respect oncology product portfolio accordingly antisoma report associate company million swiss franc goodwill arise acquisition balance acquisition price report investment associate company note consolidated financial statement transaction group associate company follow income statement income sale good supply service expense purchase good supply service balance sheet trade account receivable joint venture bayer joint venture group stake bayer roche llc joint venture bayer group overthecounter otc field market distribute product aleve andcertain otc products united states joint venture private company regi tere delaware principal executive office morristown new jersey partnership capital million dollar million swiss franc december joint venture include financial statement proportionate consolidation method chugaiaventis joint venture chugai pharma marketing ltd whollyowne subsidiary chugai stake chugaiaventis snc joint venture aventis pharma forimportation sale pharmaceutical clinical development submission application new drug joint venture partnership domicile antony france hada share capital thousand euro thousand swiss franc december thejoint venture include financial statement proportionate consolidation method effect group joint venture income statement balance sheet follow income statement sale expense net income taxis balance sheet longterm asset current asset noncurrent liabilitie current liability net asset financial longterm asset millions chf availableforsale investment heldtomaturity investment loan receivable longterm trade receivable restrict cash total financial longterm asset financial longterm asset hold strategic purpose classified noncurrent effective interest rate heldtomaturity investment loan receivable comprise loan party term year note consolidated financial statementsrestricte cash consist million dollar pay collateral deposit account respect igen litigation note million dollar cash investment pledge genen tech connection city hope litigation note million swiss franc pledge roche group company collateral connection obligation repurchase equity instrument note cash set aside collateral certain lease agreement longterm asset millions chf recognise surplus fund pension plan prepay employee benefit total longterm asset longterm asset consist asset show separately thegroup expect derive economic benefit year inventory million chf raw material supply work process finish good provision slowmove obsolete inventory total inventory inventory hold net realisable value carry value million swiss franc million swiss franc result chugai transaction inventory increase million swiss franc effective october note account receivable million chf account receivable trade note receivable provision doubtful account total account receivable december account receivable include amount denominate dollar equivalent billion swiss franc billion swiss franc amount denominate euro equivalent billion swiss franc billion swiss franc bad debt expense million swiss franc million swiss franc current asset millions chf accrue interest income prepaid expense derivative financial instrument receivables total current asset note consolidated financial statement marketable security millions chf heldfortrade investment bond debenture availableforsale current investment share bond debenture money market instrument total marketable security marketable security hold fund management purpose classified ascurrent investment hold strategic purpose classify noncurrent seenote share consist primarily readily saleable equity security bond debenture average effective contract maturity interest rate year year year total bond debenture year year year total bond debenture money market instrument generally fix interest rate range depend currency denominate contract mature year december account payable million chf account payable trade taxis payable account payable total account payable accrue current liability millions chf defer income accrue payroll relate item interest payable derivative financial instrument accrue liability total accrue current liability note consolidated financial statement equity share capital annual general meeting april shareholders approve stock split share nonvoting equity security roche holding ltd split take place number share nonvoting equity security issue respectively nominal value share swiss franc non vote equity security nominal value share information restate split take place january base information supply roche shareholder group pool voting right comprise hoffmann michalskihoffmann hoffmann hoffmann msv oerihoffmann oeri duschmaloeri oeri oeri oeri gerber group hold share share split precede year figure include share pooled voting right hold outside group individual member group transaction individual ordinary course business nonvoting equity security genussscheine december nonvoting equity security issue swiss company law nonvoting equity security nominal value share capital issue contribution show asset balance sheet roche holding ltd nonvoting equity security confer right share participate net profit remain proceed liquidation follow repayment nominal value share participation certificate accordance law article incorporation roche holding ltd company isentitle times exchange nonvoting equity security share participation certificate dividend april shareholder approve distribution dividend swiss franc share nonvoting equity security swiss franc respect business year distribution holder outstanding share nonvoting equity security total million swiss franc million swiss franc record retain earning equity instrument december number nonvoting equity security hold net cash inflow transaction equity instrument million swiss franc net cash inflow million swiss franc group hold equity instrument primarily meet obligation arise respect certain group debt instrument achieve hold physical nonvoting equity security hold forward contract derivative instrument option december group hold forward contract derivative instrument equivalent nonvoting equity security contract instrument exercise total nonvoting equity security available group note consolidated financial statement group partially cover exposure conversion sumo japanese yen exchangeable bond fully cover exposure lyon zero coupon dollar exchangeable note achieve write short option purchase long option strike price combine effect forward purchase commitment million swiss franc repurchase nonvoting equity security report debt discount present value million swiss franc note transaction support million swiss franc collateral record restrict cash financial longterm asset note earning share nonvoting equity security share information restate share split take place note basic earning share nonvoting equity security net income millions chf number share million number nonvoting equity security millions weight average number nonvoting equity security hold million total million basic earning share nonvoting equity security chf dilute earning share nonvoting equity security calculation dilute earning share nonvoting equity security weight average number share nonvoting equity securities outstanding adjust assume conversion dilutive potential share nonvoting equity security net income millions chf elimination interest expense net tax convertible debt instrument dilutive millions chf increase minority share group net income net tax assume outstanding genentech stock option exercise millions chf net income calculate diluted earning share million chf weight average number share nonvoting equity security issue million adjustment assume conversion convertible debt instrument dilutive million weight average number share nonvoting equity security issue calculate dilutive earning share millions diluted earning share nonvoting equity security chf note consolidated financial statement fair value reserve million chf fair value fair value reserve reserve available qualifying equity currency forsale cash flow conversion translation investment hedge option reserve total total beginning year change fair value recognise net income defer income taxis minority interest equity component new convertible debt currency translation gain loss total minority interest millions chf beginning year chugai disposal nippon roche minority share group net income net tax net effect movement fair value charge credit equity net effect exercise genentech stock option genentech stock repurchase dividend payment minority shareholder currency translation effect end year genentech chugai total minority interest debt million chf amount bank financial institution debt instrument capitalise lease obligation genentech synthetic lease obligation repurchase equity instrument borrowing total debt current portion longterm debt amount year total longterm debt shortterm bank loan overdraft current portion longterm debt total shortterm debt note consolidated financial statement repayment term longterm debt year year year year year total longterm debt lyon zero coupon dollar exchangeable note reflect year holder note request group purchase note fair value debt instrument billion swiss franc billion swiss franc fair value total longterm debt billion swiss franc billion swiss franc calculate base present value future cash flow instru ment discount market rate interest instrument similar credit status cash flowsand maturity period group debt unsecured note obligation arise genentech synthetic lease support restrict cash million dollar million swiss franc addition obligation secure property plant equipment cover synthetic lease net book value million swiss franc december obligation repurchase nonvoting equity security support million swiss franc ofcollateral record restrict cash financial longterm asset note amount bank financial institution interest rate amount primarily denominate dollar euro average approximately repayment date vary year debt instrument repayment samurai japanese yen bond date group repay principal billion japanese yen japanese yen bond originally issue result cash outflow million swiss franc japanese yen convertible bond issue chugai december chugai standing series chugai pharmaceutical unsecured convertible bond principal million japanese yen million swiss franc bond issue face value redemption date september bond jpy par value convertible share chugai conversion option bondholder time date bond redeemable maturity repayment bull spread dollar bond date group repay principal billion dollars ofthe dollar bond originally issue result cash outflow million swiss franc issue lyon dollar exchangeable note july group issue zero coupon dollar exchangeable note july aprincipal million dollar net proceed issue million dollar million swiss franc initially allocate million swiss franc debt million swiss franc unamortise discount million swiss franc equity respect conversion option embed bond million swiss franc ofdeferre tax liability note consolidate financial statementsthe carrying value group debt instrument give table effective interest rate swiss franc bond bullet principal billion swiss franc rodeo principal billion swiss franc dollar bond chameleon principal billion dollar japanese yen bond samurai principal billion japanese yen swiss franc convertible bond helveticus dividendlinke convertible bond principal billion swiss franc zero coupon dollar exchangeable note lyon principal billion dollar lyon iii principal billion dollar lyon principal billion dollar lyon principal billion dollar japanese yen exchangeable bond sumo principal billion japanese yen limited conversion prefer stock japanese yen convertible bond issue chugai total debt instrument swiss franc convertible bond helveticus annual payment distribution pay july bond chf par value place fix rate interest annual payment distribution equal time ordinary andor extraordinary dividend declare nonvoting equity security roche holding ltd business year end december nineteen month prior july relevant year bond exchangeable nonvoting equity security roche hold ltd time life bond accordance term bond additional cash payment chf conversion bond zero coupon dollar exchangeable note lyons note exchangeable american depositary share adss adjust exchange ratio exchange adss usd principal maturity note group purchase note cash option holder april purchase price usd principal note usd addition note redeemable option group time april issue price plus accrue original issue discount oid note consolidated financial statement lyon iii note exchangeable adss exchange ratio exchange adssper usd principal maturity note group purchase notefor cash option holder purchase price usd principal note usd usd respectively addition note redeemable option group time issue price plus accrue original issue discount oid lyon note exchangeable genentech share exchange ratio genentech share usd principal maturity note group right pay cash equal market value genentech share lieu deliver genen tech share group purchase note cash option holder january january purchase price usd principal note usd usd respectively addition note redeemable option group time january issue price plus accrue original issue discount oid lyon note exchangeable adss exchange ratio exchange adssper usd principal maturity note group purchase note cash option holder january july july apurchase price usd principal note usd usd usd respectively addition note redeemable option group inwhole time july issue price plus accrue original issue discount oid japanese yen exchangeable bond sumo bond jpy par value exchangeable nonvoting equity security roche holding ltd exchange ratio bond redeemable maturity issue price plus accrue original issue discount oid unamortised discount include carry value debt instrument follow unamortised discount swiss franc bond dollar bond japanese yen bond swiss franc convertible bond zero coupon dollar exchangeable note japanese yen exchangeable bond total unamortised discount derivative financial instrument millions chf appropriate circumstance group use derivative financial instrument risk management trading strategy discuss note derivative financial instrument carry fair value method determine fair value describe note note consolidated financial statement foreign currency derivative forward exchange contract swap option interest rate derivative swap derivative total carrying value derivative financial instrument asset liability recognise current asset accrue current liability total net asset liability recognise hedge accounting group accounting policy hedge accounting describe note require qualify hedge accounting hedging relationship meet strict condition documentation probability occurrence hedge effectiveness reliability measurement describe note group financial risk management policy cover foreign exchange risk interest rate risk market risk credit risk liquidity risk deem appropri eat certain risk alter use derivative transaction consider hedge economic term require condition meet relationship qualify hedge accounting case hedge instru ment hedged item report independently hedge relationship mean derivative report fair value change fair value include financial income expense considerable administrative cost maintain necessary documentation tracking procedure group generally limit use hedge account certain significant transaction consequently december group fair value hedge cash flow hedge hedge net investment foreign entity meet strict requirement qualify hedge accounting apart describe group subsidiary genentech describe genentech annual report quarterly sec filing genentech equity investment biotechnology company subject great risk market fluctuation stock market general manage expo sure genentech enter derivative financial instrument zero cost collar forward contract genentech nonus dollar cash flow future royalty income development expense expect year hedge transaction exposure genentech enter derivative financial instrument option forward contract genentech anticipate cash flow interestbeare investment expose change interest rate manage risk genentech enter interest rate swap agreement effectively convert expect interest income vari able fix rate swap terminate determined fore cast transaction unlikely occur gain million dollar million swiss franc recognise financial income expense movement fair value reserve designate cash flow hedge include note note consolidated financial statement provision million chf restructure provision provision total total beginning year chugai change group organisation pharmaceutical division restructure additional provision create unused amount reverse utilise year vitamin case additional provision create utilise year major legal case additional provision create utilise year provision additional provision create unused amount reverse utilise year increase discount passage time change discount rate currency translation effect end year current portion provision noncurrent portion provision total provision restructuring provision arise plan programme materially change scope business undertaken group manner business conduct provision include cost necessarily entail restructure associate theongoe activity group creation provision record charge operating income arise restructuring newly acquire company case include acquisition accounting form ofthe goodwill note pharmaceutical division restructure provision consist mainly legal environmental similar matter provision include provision respect vitamin case note major legal case note contingent liability operation earning group continue time time vary degree tobe affect political legislative fiscal regulatory development include relate environmental protection country operate industry group engage subject physical risk kind nature frequency development event cover insurance effecton future operation earning predictable note respect vitamin case note respect major legal case note consolidated financial statement cash flow statement million chf cash flow operating activity cash flow operating activity derive group primary activity asdescribe divisional review calculate indirect method adjust group operate profit operating income expense cash flow example depreciation amortisation impairment order derive cash generate operation operate cash flow show cash flow statement operate cash flow include income taxis pay activity include example taxis paidon gain labcorp share sale net income add nonoperate income expense financial income expense net impairment financial asset income taxis income applicable minority interest share result associate company operate profit depreciation property plant equipment amortisation intangible asset impairment longterm asset change group organisation chugai transaction writeoff fair value adjustment inventory charge pharmaceutical division restructuring charge vitamin case charge major legal case expense define benefit postemployment plan adjustment cash generate operation cash flow financing activity cash flow financing activity primarily proceed issue repayment group equity debt instrument include interest payment dividend payment instrument cash flow shortterm financing include finance lease include cash flow indicate group transaction provider equity debt financing cash flow shortterm borrowing show net movement consist large number transaction short maturity proceed issue longterm debt lyon zero coupon exchangeable dollar note longterm bank loan borrowing total repayment longterm debt repayment samurai japanese yen bond repayment bull spread dollar bond longterm bank loan borrowing total note consolidated financial statement interest dividend pay interest pay dividend pay total cash flow invest activity cash flow invest activity principally arise group investment inproperty plant equipment intangible asset acquisition divestment subsidiary associate company business cash flow connected group portfolio marketable security investment include interest dividend payment receive respect security investment cash flow indicate group net reinvestment itsoperate asset cash flow effect change group organisation cash generate group investment cash flow marketable security include income capital gain loss shownas net movement group portfolio consist alarge number position hold longterm basis cash flow labcorp transaction note show separate line cash flow statement cash flow respect chugai consist cash payment roche party cash hold chugai acquire acquisition subsidiary associate company product chugai antisoma amira acquisitions total divestment subsidiary associate company product neupogen divestment total interest dividend receive interest receive dividend receive total subsequent event acquisition disetronic february roche disetronic announce plan group acquire disetronic disetronic world leader research development commercialisa tion insulin pumpsand injection system treatment diabete public company headquarter burgdorf switzerland completion acquisition disetronic infusion system division roche diagnostic diabetes care business area group acquire disetronic injection system sell disetronic founder chairman continue operate independent company group offer shareholder disetronic swiss franc cash roche non vote equity security disetronic share propose acquisition subject approval competition authoritie disetronic shareholder total cost theacqui sition expect approximately billion swiss franc expect proceed resale injection system division order million swiss franc note consolidated financial statementsreport group auditor general meeting roche holding ltd basel auditor group audit consolidated financial statement roche group page year end december consolidated financial statement responsibility board director roche holding ltd responsibility express opinion consolidated financial statement base audit confirm meet swiss legal requirement con cerne professional qualification independence audit conduct accordance auditing standard promulgate swiss profession international standard auditing require audit plan perform obtain reasonable assurance consolidated financial statement free material misstatement examine test basis evidence support amount disclosure consolidate financial statement alsoassesse accounting principle significant estimate overall consolidated financial statement presentation believe audit provide reasonable basis opinion opinion consolidate financial statement roche group present fairly material respect financial position december result operation cash flow year end accordance international financial reporting standard comply swiss law recommend consolidated financial statement submit approve pricewaterhousecoopers william kirst clive bellingham basel february report group auditor multiyear overview statistic report statement income millions chf sale ebitda operating profit net income research development balance sheet million chf longterm asset current asset total asset equity minority interest noncurrent liability current liability addition property plant equipment personnel number employee end year key ratio net income sale net income equity research development sale current ratio equity minority interest total asset sale employee thousand chf data share nonvoting equity security number share number nonvoting equity security genussscheine total share nonvoting equity securities total dividend million chf earning share nonvoting equity security dilute chf dividend share nonvoting equity security chf cash warrant addition dividend adjust chf cash warrant addition dividend unadjuste chf information table state report change accounting policy arising change international financial reporting standard andthe stock split arenot apply retrospectively warrant hold final exercise date addition normal dividend shareholder approve share nonvoting equity security special centenary warrant worth chf date issue holder option cash equivalent chf net income relate key ratio show special charge million swiss franc net tax incur follow corange acquisition include corange respect balance sheet datum multiyear overview warrant hold final exercise date dividend include special dividend relate spinoff fragrance flavour division dividend propose board director multiyear overview sale division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour total sale geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total multiyear overviewaddition property plant equipment division millions chf pharmaceutical diagnostic vitamin fine chemical fragrance flavour total addition property plant equipment geographical area millions chf switzerland european union rest europe europe north america latin america japan rest asia asia africa australia oceania total multiyear overview roche security share price performance chf roche share adjust swiss market index rebase nonvoting equity security genussschein price performance chf roche nonvoting equity security adjust swiss market index rebase american depositary receipt adr price performance usd roche adr adjust index rebase roche american depositary receipt adr equivalent nonvoting equity security genussschein adrs trade united states overthecounter market july roche securitiesnumber share nonvoting equity securitiesa number share nominal value chf chf number nonvoting equity security genussscheineno nominal value total datum share nonvoting equity securityc chf net income equity dividend stock price shareb high low yearend stock price nonvoting high equity security low genussscheinb yearend historic stock price unadjuste share yearend nonvoting equity security genussschein yearend market capitalisation unadjuste millions chf yearend key ratio yearend net income equity dividend yield share dividend yield nonvoting equity security genussscheinein priceearning share unadjuste priceearning nonvoting equity security genussscheine unadjuste nonvoting equity security genussschein confer right share participate avail able earning remain proceed liquidation follow repayment nominal value share participation certificate capital share nonvoting equity security list swiss exchange roche holding ltd restriction ownership share nonvoting equity securities stock price datum reflect daily closing price stock price figure prior june adjust effect givaudan spinoff adjustment factor share nonvoting equity security factor independent financial institution net income share prior market capitalisation figure assume equity instrument hold outstanding dividend include special dividend relate spinoff fragrance flavour division dividend propose board director ticker symbol share nonvoting american equity security depositary receipt reuter roczs roczgs rohhypk bloomberg rog rohhy swx swiss exchange rog roche security outstanding issue summarise issue term exchange term warrant lyons april note exchangeable american depositary share face value usd adss adjust exchange ratio exchange coupon zero adss usd principal maturity note issuer roche holdings inc exchange ratio change accordance inden roche hold ltd ture agreement date april effective date exchange right roche adss group purchase note cash roche time april option holder april purchase price perusd principal note usd inaddition note redeemable option group time april theissue price plus accrue original issue discount oid helveticus july bond chf par value exchangeable hun face value chf dre nonvoting equity security roche holding ltd coupon times ordinary andor time life bond accordance term extraordinary dividend nonvoting bond additional cash payment chf equity security genussscheine conversion bond chf par value issuer roche capital market international limited roche holding ltd conversion right roche nonvoting equity security genussscheine lyon iii note exchangeable american depositary share face value usd adss exchange ratio exchange adss coupon zero usd principal maturity note exchange issuer roche holdings inc ratio change accordance indenture agreement roche holding ltd date effective date exchange right roche adss group purchase note cash option holder roche time purchase price usd principal note usd usd respectively addition note redeemable option group time issue price plus accrue original issue discount oid rodeo march warrant expire unexercised march face value chf coupon issuer roche kapitalmarkt roche holding ltd attach warrant roche nonvoting equity security genussscheine bullet march face value chf coupon issuer roche international finance corporation limit roche hold ltd roche securitiesoutstanding issue summarise issue term exchange term warrant chameleon july face value usd coupon issuer roche holdings inc roche holding ltd lyon january note exchangeable genentech share face value usd exchange ratio genentech share usd coupon zero principal maturity note group issuer roche holdings inc right pay cash equal market value genentech roche holding ltd share lieu deliver genentech share group exchange right genentech common stock willpurchase note cash option holder roche time january january january purchase price usd principal note usd andusd respectively addition note redeemable option group anytime january issue price plus accrue original issue discount oid sumo march bond jpy par value exchangeable face value jpy nonvoting equity security roche holding ltd coupon exchange ratio bond redeemable issuer roche holdings inc maturity issue price plus accrue original issue roche holding ltd discount oid exchange right roche nonvoting equity security genussscheine accordance term bond exchange ratio adjust june lyon july note exchangeable american depositary share face value usd adss exchange ratio exchange adss coupon zero usd principal maturity note group issuer roche holdings inc purchase note cash option holder roche holding ltd january july july pur exchange right roche adss chase price usd principal note roche time july ofusd usd usd respectively inaddition note redeemable option thegroup time july attheissue price plus accrue original issue discount oid roche security roche holding ltd basel financial statement income statement millions chf income income participation interest income loan group company interest investment income income total income expense financial expense administration expense expense total expense profit year taxis tax net profit year financial statementsbalance sheet december millions chf longterm asset participation loan group company total longterm asset current asset account receivable group company account receivable prepay expense accrue income marketable security liquid fund total current asset total asset equity share capital nonvoting equity security genussscheine general legal reserve free reserve special reserve available earning balance bring forward previous year net profit year total equity noncurrent liability provision total noncurrent liability current liability account payable group company liabilitie accrue liability total current liability total liability total equity liability pro memoria nonvoting equity security nominal value financial statement note financial statement general financial statement roche holding ltd basel prepare accordance provision swiss company law accept business principle valuation method translation foreign currency balance sheet asset liability disclose net realisable value exception tothis rule participation show acquisition value appropriate writedown marketable security show low cost market value unrealise foreign currency gain balance sheet item defer expense income aswell foreign currency transaction translate exchange rate rule relevant transaction date detail specific item income total income million swiss franc million swiss franc higher previous year mainly well operate income taxis tax charge include corporate income capital taxis withhold taxis stamp duty equity total equity equal total asset share capital previous year share capital amount million swiss franc share capital consist bearer share nominal value swiss franc nonvoting equity security genussscheinewith nominal value guarantee guarantee favour group company total million swiss franc previous year million swiss franc time prepare balance sheet risk arise contingent liability discernible pledge asset asset total book value million swiss franc previous year pledge security company commitment note financial statementsparticipation major participation list page important shareholder share company issue bearer reason company notkeep register shareholder follow figure base information share holder shareholder validation check annual general meeting april onother information available company previous year share shareholder group pool voting right comprise hoffmann michalskihoffmann hoffmann hoffmann msv oerihoffmann oeri duschmaloeri oeri oeri oeri anddr gerbera share novartis international ltd basel include affiliate thereofb information supply shareholder december figure share include share pooled voting right hold outside group individual member group figure december supply novartis international ltd basel note financial statement appropriation available earning proposal general meeting chf available earning net profit year balance bring forward previous year total available earning appropriation available earning distribution ordinary dividend chf gross share nonvoting equity security genussschein chf year transfer free reserve total appropriation available earning carry forward account appropriation available earningsreport statutory auditor general meeting roche holding ltd basel statutory auditor audit accounting record financial statement income statement balance sheet note page roche holding ltd basel forthe year end december financial statement responsibility board director responsibility toexpress opinion financial statement base audit confirm meet legal requirement concern professional qualification independence audit conduct accordance auditing standard promulgate swiss profession require audit plan perform manner obtain reasonable assurance financial statement free material mis statement examine test basis evidence support amount disclosure inthe financial statement assess accounting principle significant estimate overall financial statement presentation believe audit pro vide reasonable basis opinion opinion accounting record financial statement propose appropriation available earning comply swiss law company article incorporation recommend financial statement submit approve ernst young ltd conrad lffel jrg zrcher basel february report statutory auditor arctic circle tropic cancer tropic capricorn roche rcrc letic global market presence sale switzerland manufacture argentina research development australia toe mic rii party austria bangladesh belgium bermuda brazil canada chile china colombia costa rica czech republic denmark dominican republic ecuador egypt salvador finland france germany great britain greece guatemala roche global market presence arctic circle tropic cancer tropic capricorn cnt rcrc letic guernsey south africa honduras south korea hungary spain india sweden indonesia taiwan ireland thailand israel turkey italy uruguay japan usa malaysia venezuela mexico vietnam morocco netherlands new zealand nicaragua norway pakistan panama peru philippine poland portugal puerto rico russia singapore roche global market presence subsidiary associate company group hold interest switzerlandf hoffmannla roche ltd basel roche vitamins canada inc cambridge ontario mostofthe company list exception chf roche ltd sisseln chf sapac corporation ltd chempharm aremarke single dot teranol ltd lalden chf roche pharma limited cad chileproducto roche ltda group interest switzerland ltd reinach roche diag santiago chile mxn roche vitaminas double dot nostic schweiz ltd rotkreuz chf chile puerto varas usd china group interest roche diagnostic international ltd cham rocheshanghai fine chemicals ltd shanghai chf roche vitamin europe ltd birs usd roche china limited shanghai share capital show million local felden chf roche instrument center ltd usd shanghai roche pharmaceutical currency rotkreuz chf roche consumer health limit shanghai usd roche shanghai share capital local currency ltd kaiseraugst chf roche vitamins ltd vitamins ltd shanghai usd roche unit basel chf imib institute medical zhongya wuxi citric acid ltd wuxi usd informatics biostatistics ltd basel chf roche diagnostic shanghai limited shanghai basilea pharmaceutica ltd basel chf usd roche hong kong limited hong include change group membership roche finanz basel chf roche kong hkd roche diagnostic hong february kapitalmarkt basel chf roche trea kong limited hong kong hkd sury management europe ltd basel chf colombiaproducto roche bogot roche vitamin hold basel chf cop roche vitaminas colombia roche holding basel chf valor bogot cop costa ricaroche servi fide chur chf syntex corporation cios san jos usd roche vitaminas basel chf rabbitair ltd zurichkloten costa rica san jos usd productos chf pharmexbio ltd zug chf roche san jos usd czech republic argentinaproductos roche qumica roche sro prague czk denmark industrial buenos aire ars roche vita roche hvidovre dkk roche vitamin minas argentina buenos aire ars hvidovre dkk dominican republic australiaroche products pty limited dee productos rochedominicana santo aud roche vitamin australia pty domingo dop roche vitaminas domini limited french forest aud syntex aus cana santo domingo dop ecuador tralia limited north sydney aud roche roche ecuador quito usd roche diagnostic australia pty limited castle hill vitaminas ecuador quito usd egypt aud austriaroche austria gmbh rovigypt ltd giza egp roche egypt vienna eur roche diagnostic gmbh ltd giza egp salvadorproducto vienna eur bangladeshroche roche elsalvador san salvador usd bangladesh ltd dhaka bdt belgiumnv finlandroche espoo eur france roche brussels eur sacitrique hoffmannlaroche france sas neuillysur belge tienen eur roche vitamin seine eur roche neuillysurseine deinzeastene eur rochediag eur roche diagnostic meylan nostics belgium brussels eur eur roche vitamine france bermudacorange ltd hamilton usd villageneuf eur laboratoire roche roche capital transactions limited hamilton nicholas gaillard eur germany usd roche financial product limit roche deutschland hold gmbh grenzach hamilton usd roche international wyhlen dem corange deutschland finance bermuda ltd hamilton usd hold gmbh mannheim eur consulab roche international ltd hamilton usd mannheim gmbh mannheim eur canadian pharmholding ltd hamilton pharma waldhof gmbh mannheim usd corange international ltd hamilton eur hoffmannla roche aktienge usd roche capital management ltd hamilton sellschaft grenzachwyhlen eur roche usd roche intertrade ltd hamilton consumer health deutschland gmbh eppstein usd syntex pharmaceutical eur roche diagnostic gmbh mannheim international ltd hamilton usd roche eur galenus mannheim gmbh healthcare limited hamilton usd brazil mannheim eur hestia health care produto roche qumico farmacuticos gmbh mannheim eur roche vitamine paulo brl roche diagnostic brasil gmbh grenzachwyhlen eur great ltda paulo brl roche vitaminas britainroche product limit welwyn garden brasil ltda paulo brl canada city gbp roche diagnostics ltd lewes hoffmannlaroche limited toronto cad gbp roche vitamin ltd welwyn subsidiary associate companiesgarden city gbp roche registration new zealand pty ltd auckland nzd ticaret istanbul trl roche limited welwyn garden city gbp roche nicaraguaproducto roche nicaragua vitaminleri limited sirketi istanbul hold limited welwyn garden city managua nio norwayroche norge trl uruguayroche international ltd uruguay gbp antisoma plc london greeceroche oslo nok pakistanroche pakistan ltd montevideo sapac corporation ltd uruguay hellas athens eur roche vita karachi pkr panamaproducto roche montevideo roche vitaminas uruguay mins hellas epe athens eur roche interamericana panama city usd montevideo uyp usaroche holdings vitamin international marketing centre epe producto roche panam panama city inc wilmington delaware usd athens eur guatemalaproductos roche pab roche vitaminas interamrica panama hoffmannlaroche inc nutley new jersey guatemala guatemala gtq roche city usd roche capital corporation usd roche laboratories inc nutley vitaminas guatemala guatemala gtq panama city roche financial management newjersey roche vitamin inc guernsey roche capital market international inc panama city chf syntex corporation parsippany new jersey usd roche limit stpeter port chf roche inter panama city usd peruproductos roche molecular systems inc pleasanton california national finance corporation limited peter qumica farmacutica lima pen american roche international inc little fall port chf roche financial market limited roche vitaminas lima pen new jersey cad roche carolina inc peter port guernsey chfhonduraspro philippinesroche philippines inc makati florence southcarolina genentech inc ducto roche honduras tegucigalpa php roche vitamin philippines inc south san francisco california usd hnl roche vitaminas centroamricana caribe manila php polandroche polska roche palo alto llc palo alto california puerto cort hnl hungaryroche spzoo warsaw pln roche diagnostic usd roche colorado corporation boulder hungary ltd budapest huf roche vita polska warsaw pln roche colorado usd bayerroche llc mins hungary ltd ujhartyan huf india witaminy polska zoo mszczonw morristown new jersey usd roche roche scientific company india private limited pln portugalroche farmacutica qumica lda diagnostic corporation indianapoli indiana mumbai inr roche diagnostic india amadora eur roche sistemas diag usd venezuelaproducto roche pvtltd mumbai inr indonesiapt roche nsticos sociedade unipessoal lda lindaa caracas veb roche vitaminas indonesia jakarta idr irelandroche velha eur puerto ricosyntex puerto venezuela lavictoria vebvietnam products ireland limited dublin eur rico inc humacao usd russiaroche roche vitamin vietnam limited binhduong roche ireland limited clarecastle eur moscow ltd moscow rub singapore province usd israelroche pharmaceutical israel ltd tel roche singapore pte ltd singapore sgd aviv italyroche spa milan eur roche diagnostic asia pacific pte ltd singa roche diagnostic spa milan eur pore sgd roche vitamin asia pacific istituto delle vitamine spa milan eur pte ltd singapore sgd boehringer japan chugai pharmaceuticals ltd tokyo mannheim far east pte ltd singapore jpy nutritec ltd tokyo sgd south africaroche product proprietary jpy roche diagnostic tokyo limited johannesburg zar roche vita jpy roche vitamin japan tokyo mins south africa pty limited johannesburg jpy malaysiaroche malaysia sdn bhd zar south korearoche korea company kuala lumpur myr roche diagnostics ltd seoul krw roche diagnostic malaysia sdn bhd kuala lumpur myr korea ltd seoul krw roche roche vitamin malaysia sdn bhd kuala vitamins korea ltd seoul krw lumpur myr mexicoproductos roche spainroche farma madrid eur mexico city mxn syntex roche vitaminas madrid eur mexico city mxn grupo roche andreu roche madrid eur syntex syntex mxico mexico city roche madrid eur roche diagnos mxn lakeside mxico mexico tic barcelona eur boehringer city mxn roche vitaminas mxico mannheim roche madrid eur swe salto jalisco mxn morocco denroche stockholm sek roche roche casablanca mad roche diagnostic scandinavia bromma sek immobilire maroc sarl casablanca taiwanroche products ltd taipei twd mad thenetherlandsroche pharmholde roche diagnostics ltd taipei twd mijdrecht eur roche nederland roche vitamin taiwan limited taipei mijdrecht eur roche diagnostic twd thailandroche thailand limited bangkok nederland almere eur roche vita thb rovithai limited bangkok mins venlo eur new zealandroche thb roche diagnostic thailand limited product new zealand limited auckland bangkok thb turkeyroche nzd roche vitamin new zealand lim tahzarlari sanayi anonim sirketi istanbul ited auckland nzd roche diagnostic trl roche diagnostik sistemleri subsidiary associate company cautionary statement forwardlooke statement annual report contain certain forward opment economic condition delay look statement forwardlooke inability obtain regulatory approval bring statement identify byword ing product market fluctuation currency believe expect anticipate project intend exchange rate general financial market seek estimate future similar condition uncertainty discovery devel expression discussion opment market new product new use thing strategy goal plan intention exist product increase government factor cause actual result differ materially price pressure interruption production future reflect forwardlook loss inability obtain adequate protection ing statement contain annual report intellectual property right litigation price product initiative loss key executive orother employee ofcompetitor legislative regulatory devel adverse publicity news coverage publish hoffmannla roche ltd basel switzerland tel fax medium office corporate communication basel switzerland tel fax investor relations basel switzerland tel fax world wide web httpwwwrochecom order tel fax publication email baselwebmasterrochecom annual general meeting april trademark mention enjoy legal protection roche annual report publish german original language english roche annual report issue hoffmannla roche ltd basel corporate communication design wirz identity zurich photo mike frei zurich roche corporate photolibrary basel typeset staufferfebel basel lithos lithoteam allschwilbasel printer birkhusergbc reinachbasel bind buchbinderei grollimund reinachbasel cover vascular disease crystal neprilysin human neutral endopeptidasediagnostic sale division pharmaceutical asia latin america sales region europe north america diagnostic employee division pharmaceutical latin america asia north america employee region europe adjust basis